

CURRICULUM VITAE

Bronwen E. Shaw MBChB, PhD

**Center Director, Professor
Department of Medicine
Division of Hematology and Oncology - Medicine**

OFFICE ADDRESS:

Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226
Phone: 414-805-0700
Fax: 414.805.0714
Email: beshaw@mcw.edu

EDUCATION:

1988 - 1993 MB ChB, University of Cape Town, South Africa
07/1996 Royal College of Physicians (London) Part I (Membership), United Kingdom
07/1997 Royal College of Physicians (London) Part II (Membership), United Kingdom
2000 Royal College of Pathologists (London) Part I (Membership), United Kingdom
11/2004 PhD in Clinical Sciences, University College London, United Kingdom
09/2005 Royal College of Pathologist (London) Part II (Membership), United Kingdom

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

1994 House Officer, Groote Schuur University Hospital, Cape Town, South Africa
04/1995 - 11/1997 Medical Senior House Officer Rotation, London, United Kingdom
12/1997 - 06/2000 Haematology Specialist Registrar, North West Thames, Ealing Hospital, Royal Free Hospital, Northwick Park Hospital, United Kingdom
07/2000 - 07/2004 Research Fellow, Anthony Nolan Research Institute, London, United Kingdom
01/2001 - 06/2004 Medical Officer, Anthony Nolan Research Institute, London, United Kingdom
08/2004 - 08/2006 SpR in Haematology, Specialist interest in Blood and Bone Marrow Transplant, Nottingham City Hospital, United Kingdom

FACULTY APPOINTMENTS:

10/2006 - 11/2006 Locum Consultant, Lymphoma and General Haematology, St. Marys Hospital, London, United Kingdom
12/2006 - 01/2007 Locum Consultant, Lymphoma and general Haematology, Nottingham City Hospital, Nottingham, United Kingdom
04/2007 - 07/2014 Chief Medical Officer and Head of the Clinical Research Group, Anthony Nolan, London, United Kingdom
04/2007 - 07/2014 Clinical Senior Lecturer and Honorary Consultant in Blood and Marrow Transplantation, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, United Kingdom
09/2014 - Present Professor of Medicine, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226
09/2014 - 01/2019 Senior Scientific Director, Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Froedert & the Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226
02/2019 - 01/2021 Associate Chief Scientific Director, Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Froedert & the Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226
02/2021 - Present Chief Scientific Director, Center for International Blood and Marrow Transplant Research

(CIBMTR), Division of Hematology and Oncology, Froedert & the Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226

RESEARCH ADMINISTRATIVE APPOINTMENTS:

09/2014 - Present Senior Scientific Director - Data Operations, Department of Medicine, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, 9200 West Wisconsin Avenue, CCC, Suite C5500, 5th Floor, Milwaukee, WI 53226

AWARDS AND HONORS:

2006 BSBMT Scientific day Best abstract, British Society of Blood and Marrow Transplantation
2007 EBMT Von Bekkum award Best abstract, European Society for Blood and Marrow Transplantation
2022 Outstanding Faculty Service Award, Medical College of Wisconsin
2022 Department of Medicine's Michael J. Dunn Research Award, Medical College of Wisconsin

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

2014 - Present S(P)EAR Committee of the World Marrow Donor Association (WMDA) (Member (Past-chair))
2021 - 2023 World Marrow Donor Association (President)
European Society for Blood and Marrow Transplantation (EBMT) (Member)
British Society for Blood and Marrow Transplantation (BSBMT) (Member)
American Society for Cellular Therapy and Transplantation (ASTCT)
American Society for Blood and Marrow Transplantation (ASBMT) (Member)
British Society of Haematology (BSH) (Member)
American Society of Haematology (ASH) (Member)
European Federation of Immunogenetics (EFI) (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Editorial Board

03/2008 - 03/2014 Bone Marrow Transplantation
2011 - Present Frontiers in Alloimmunity and Transplantation
01/01/2016 - Present Tissue Antigens
2016 - Present HLA
2017 - Present Advances in Cell and Gene Therapy
2018 - Present Biology of Blood and Marrow Transplantation

Journal Review

Lancet Oncology
Blood
Hematology
Transplantation
Haematologica
JCO
Bone Marrow Transplantation

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

2012 - 2014 Co-Chair, Donor Health and Safety Committee, Center for International Blood and Marrow Transplant
09/2014 - Present Member, Histocompatibility Advisory Group, National Marrow Donor Program
2014 - 2019 Scientific Director, Late Effects and Quality of Life Committee, Center for International Blood and Marrow Transplant Research
2014 - Present Scientific Director, Donor Health and Safety Committee, Center for International Blood and Marrow Transplant Research
2015 - 2016 Co-Chair, Research Methodology and Study Design Working Group, NIH BMT Late Effects Consensus Conference
2015 - 2021 Co-Chair, Foundation for the Accreditation of Cellular Therapy (FACT)-Center for International Blood and Marrow Transplant Audit Committee
2016 - 2019 Member, Council for Women's Advocacy
2016 Co-Chair, Research Methodology and Study Design Working Group, NIH BMT Late Effects Consensus

Conference
 2016 - 2017 Member, Steering Committee (collaborator), NMDP: Engaging Patients in Developing a Patient-Centered Hematopoietic Cell Transplant Research Agenda (EAIN-2956)
 2017 - Present Member, External Advisory Board for the Pediatric Proton Consortium Registry (PPCR)
 2018 - 2021 Associate Program Director for Fellowship, Hematology-Oncology Fellows, Medical College of Wisconsin
 2018 - 2021 Co-Chair, Investigator Initiated Trial Steering Committee, MCW
 2019 - Present Member, American Cancer Society Institutional Research Grant (ACS-IRG) Review Committee, Medical College of Wisconsin Cancer Center
 2019 - 2021 Member, Steering Committee, ASTCT Biobehavioral Research SIG
 2020 - 2023 Member, Rank Committee, Medical College of Wisconsin, School of Medicine
 2022 - Present Faculty, Annual Leadership Course, ASTCT

INTERNATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

2008 - 2014 Board Member, World Marrow Donor Association
 2008 - 2014 Chair, Clinical Working Group, World Marrow Donor Association
 2009 - 2014 Member, Medical Advisory Group, Anthony Nolan, London, United Kingdom
 2009 - 2014 Member, Program Committee, IDRC
 2009 - 2014 Member, United Kingdom Cord Blood Working Group
 2010 - Present Member, Donor Standing Committee, Worldwide Network for Blood and Marrow Transplantation
 2011 - 2014 Member, Medical Advisory Group, United Kingdom Strategic Stem Cell Forum
 2011 - 2014 Faculty, European Society for Blood and Marrow Transplantation (ESH-EBMT) Training Course on Haemopoietic Stem Cell Transplantation, European School of Haematology
 2011 - 2021 Member, World Health Organization (WHO) NOTIFY Group for Vigilance and Surveillance
 2011 - 2021 Member, Advisory Committee for 5th and 6th Edition of the FACT/JACIE Clinical Standards
 2011 - 2014 Member, Executive Board, British Society of Blood and Marrow Transplantation (BSBMT)
 2011 - 2019 Editorial Lead, World Health Organization (WHO) NOTIFY Group for the Living Donor Group
 2012 - 2014 Chair, Clinical Trials Committee, British Society of Blood and Marrow Transplantation (BSBMT)
 2012 - 2014 Chair, Education Group, British Society of Blood and Marrow Transplantation (BSBMT)
 2012 - 2014 Member, Clinical Excellence Award Selection Review Committee, British Society of Blood and Marrow Transplantation (BSBMT)
 2013 - 2017 Member, Research Oversight Committee, Genome Quebec: Personalised Cancer Immunotherapy
 2014 - 2019 Member (Past Chair), S(P)EAR Committee, World Marrow Donor Association
 2014 Program Chair, International Donor Registry Conference (IDRC), London
 2014 - Present Program Chair, IDRC
 2018 - Present Member - Expert Scientific Panel, IMPACT Clinical Trials Committee, Leuka
 2018 - Present Expert Review Panel Member, Canadian National Transplant Research Program
 2019 - 2021 President-Elect and Chair, Donor Pillar, WMDA
 2021 - 2023 President, World Marrow Donor Association

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Active

Peer Review

Title:	Integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantation
Source:	Fred Hutchinson Cancer Research Center
Role:	Co-Investigator
PI:	Karen Syrjala
Dates:	05/01/2017 - 04/30/2022
Direct Funds:	\$34,050

Title: Identifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell Donors
Source: NIH
Role: Co-Investigator
PI: Galen Switzer
Dates: 01/01/2018 - 12/31/2022
Direct Funds: \$111,058

Title: Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR)
Source: NCI
Role: Co-Investigator
Dates: 08/30/2018 - 06/30/2023
Direct Funds: \$6,620,593

Title: A Data Resource for Analyzing Blood and Marrow Transplants
Source: NIH/NCI
Role: Co-Investigator
Dates: 09/17/2018 - 02/28/2023
Direct Funds: \$15,441,954

Title: DCC for 1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
Source: NHLBI
Role: Principal Investigator
Dates: 04/01/2022 - 03/31/2029

Title: HRSA: Stem Cell Therapeutic Outcomes Database
Role: Co-Investigator and Research Director
Dates: 09/27/2022 - 09/26/2027

**Prior
Peer Review**

Title: Gilead Antifungal Audit. £20,000
Role: Principal Investigator
Dates: 2009 - 2010

Title: Higher Education Funding Council for England - Clinical Senior Lecturer Fellowship. £250,000
Role: Principal Investigator
Dates: 2010 - 2014

Title: MD Fellowship in Graft versus Host Disease. £75,000
Role: Principal Investigator
Dates: 2010 - 2012

Title:	Next 7 steps. £15,000
Role:	Principal Investigator
Dates:	2012
Title:	Immune Reconstitution in Cord Blood Transplantation. £124,000
Role:	Co-Principal Investigator
Dates:	2012 - 2015
Title:	Ethnic factors leading to donor attrition. £330,000
Role:	Co-Principal Investigator
Dates:	2013 - 2016
Title:	Tree ensemble models for high dimensional survival analysis with predictions using large databases
Source:	Advancing a Healthier Wisconsin
Role:	Co-investigator
PI:	Brent Logan
Dates:	2015 - 2017
Direct Funds:	\$200,000
Title:	Stem Cell Therapeutic Outcomes Database
Source:	HRSA
Role:	Co-Investigator
PI:	Doug Rizzo
Dates:	09/27/2017 - 09/26/2022
Direct Funds:	\$18,611,238
Title:	Quality of Life in Older Patients Receiving Hematopoietic Cell Transplantation for Blood Disorders
Source:	MCW Cancer Center Grant
Role:	Principal Investigator
Dates:	12/01/2017 - 11/30/2019
Direct Funds:	\$49,715
Title:	Bayesian Ensemble Models for Time to Event Data and Individualized Treatments
Source:	MCW Cancer Center Pilot Grant
Role:	Co-Investigator
Dates:	06/01/2018 - 05/31/2019
Direct Funds:	\$39,995
Title:	Incorporating patient reported outcomes into individualized prognostication tools for survival and quality of life in transplant patients
Source:	NHLBI
Role:	Principal Investigator
Dates:	08/01/2018 - 06/30/2019
Direct Funds:	\$160,744

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

Local

QOL in Hematopoietic Cell Transplantation, Department of Medicine Research Retreat, Milwaukee, WI, 02/2018

A long journey of collaboration to improve transplant outcomes by 'clever' donor matching. With Katharina Fleischhauer, The first Anna Stadnicka Endowed speaker talk, Milwaukee, WI, 11/2018

The art and compassion of Medicine, MCW white coat ceremony, Milwaukee, Wisconsin USA, 08/2019

National

DPB1 T-Cell Epitope Matching in HSC Transplant, Georgetown Lecture Series, Live Online, 06/2013

Donor Safety and Donor Selection Criteria, National Marrow Donor Program Board Meeting, Las Vegas, Nevada, 06/2013

Patient Illness Session, National Marrow Donor Program Council Meeting, Minneapolis, Minnesota, 11/2014

Haploidentical Transplants: trends and opportunities, National Marrow Donor Program Board Meeting, Los Angeles, California, 01/2015

How to select a donor and product for allogeneic HCT, BMT Tandem Meeting, San Diego, California, 02/2015

Non HLA donor factors for selection, NMDP Council meeting, Minneapolis, MN, 11/2015

Diagnosis to Infusion, NMDP Council meeting, Minneapolis, MN, 11/2015

Unrelated Donor Selection: HLA and other donor characteristics, Memorial Sloan Kettering Cancer Center, New York, 03/2016

Relapse in BMT, BMT Winter Workshop, San Diego, California, 12/2016

Meet the experts: Donor selection, BMT Tandem Meetings, Orlando, Florida, 02/2017

Impacting Clinical Practice through Participation: CIBMTR orientation, BMT Tandem Meeting, Orlando, Florida, 02/2017

External Advisory Board Meeting, Pediatric Proton Consortium Registry, Boston, MA, 05/2017

Unrelated Donor Selection: HLA and other donor characteristics, Oregon Health & Science University, Portland, OR, 08/2017

A resource for transplantation: Update of the Center for International Blood and Marrow Transplant Research (CIBMTR), Oregon Health & Science University, Portland, OR, 08/2017

Beyond HLA: What non-HLA characteristics are being considered in donor selection today?, NMDP Council Meeting, Minneapolis, MN, 11/2017

The impact of QOL on Hematopoietic Cell Transplantation, BMT Tandem Meeting, Salt Lake City, UT, 02/2018

2018 Donor and Cord Blood Selection Guidelines, NMDP Council Meeting, Minneapolis, MN, 11/2018

Secondary Cancers post BMT, TCT meeting, Houston, USA, 02/2019

Patient-reported outcomes (PROs in Hematopoietic Cell Transplantation, Mayo Clinic Grand rounds, Phoenix, USA, 04/2019

Patient-reported outcomes (PROs) in Hematopoietic Cell Transplantation, Cleveland Clinic Grand rounds, Cleveland, USA, 07/2019

What We Can Learn from International Regulatory Agencies and Registries: CIBMTR, Cord Blood Connect meeting, Miami, USA, 09/2019

How to Design a Multi-Center Trial with Little Funding and No Involvement of BMT CTN, Cord Blood Connect meeting, Miami, USA, 09/2019

Harnessing Technology, Big Data, and PROs to Reduce Toxicities and Symptoms After HCT and Cellular Therapy, Keynote Speaker: 2nd International Symposium on Biology, Prevention, and Treatment of Toxicities After Transplantation and Cellular Therapy, New York, USA, 10/2019

CIBMTR As a Resource for Epidemiology Research for Myeloid Malignancy, ASH, Orlando, USA, 12/2019

Assuring the safety of volunteer unrelated donors, TCT, Orlando, USA, 02/2020

Matched and Mismatched unrelated donor transplantation, New York Academy of Sciences, Frontiers in cancer immunotherapy, Virtual, 05/2021

Patient-specific selection of unrelated donors to optimize allogeneic hematopoietic cell transplant outcomes, Grand Rounds, Dana Faber Cancer Center, Virtual, 11/2021

How I treat adult patients with no available matched donors, NMDP One forum, Virtual, 11/2021

Improving Outcomes and Expanding Access to Unrelated Donor Transplants, Grand rounds, University of Birmingham, Alabama, Virtual, 12/2021

Women in Cellular Therapy Keynote OR a tale of (a few) cities Women in cellular therapy day., 2nd Midwest

Cellular Conference, Rush University, Chicago, Illinois, 04/2022
How to Use Registry Data Wisely and Perform in Multicenter Trails, Clinical Research Training Course, Park City, UT, 07/2022

International

Mismatches and more mismatches, Current Issues in Haematopoietic Stem Cell Transplantation, Royal Free Hospital, London, United Kingdom, 01/2003

Potential immunosuppressive effects of CMV in unrelated stem cell transplantation, Immunobiology Working Party, European Society for Blood and Marrow Transplantation, Istanbul, Turkey, 07/2003

The impact of HLA-DPB1 antigen and allele mismatches in unrelated donor HCT, Immunobiology Working Party, European Society for Blood and Marrow Transplantation, Prague, Czech Republic, 03/2005

The Anthony Nolan Experience, outcome data on 423 transplant pairs and donor selection algorithms. Topical issues in unrelated donor Haematopoietic Stem Cell Transplants: a workshop convened by the Anthony Nolan trust, London, United Kingdom, 06/2005

Major Histocompatibility antigens: the clinical impact of HLA mismatches and donor selection strategies, Immunogenetics in Haematology and Stem Cell Transplantation, Polish Society of Immunogenetics, Wroclaw, Poland, 02/2006

Factors impacting on the success of DLI in recipients of reduced intensity conditioned transplants, Immunobiology Working Party, European Group for Blood and Marrow Transplantation, Lyon, France, 03/2007

Finding a donor for stem cell transplantation: registries, regulations and outcomes, Educational Day, Princess of Wales Hospital, Wales, United Kingdom, 04/2008

GvHD/GvL, British Society for Histocompatibility and Immunogenetics Spring Training Day, Birmingham, England, United Kingdom, 05/2008

The Role Of HLA-DPB1 In The Outcome Of Unrelated Donor Hematopoietic Stem Cell Transplantation; The Reduced Intensity conditioning-indications, implications and outcomes; Donor Lymphocytes Infusions, Second Transplants And Other Options For Preventing And Treating Disease Relapse Post transplantation, 23rd Current Course on Molecular Genetics, American Society for Histocompatibility and Immunogenetics, Mexico City, Mexico, 08/2008

Understanding HLA and donor selection strategies, British Society of Blood and Marrow Transplantation Educational Day, London, United Kingdom, 10/2008

Alternative donors and cord blood transplantation, Haematological Malignancies, London, United Kingdom, 06/2009

Graft Identification Advisory Service (GIAS), Joint Symposium on Cord Blood Transplantation - Future Challenges, London, United Kingdom, 10/2009

Advances in transplantation, HAEMATOLOGICAL MALIGNANCIES, London, United Kingdom, 06/2010

GCSF in normal donors, GCSF Symposium, Barcelona, Spain, 06/2010

The Role Of HLA-DPB1 In The Outcome Of Unrelated Donor Hematopoietic Stem Cell Transplantation, Donor selection for transplantation, Disease Relapse Post transplantation, 25th Current Course on Molecular Genetics, American Society for Histocompatibility and Immunogenetics, Mexico City, Mexico, 08/2010

Alternative Donor Transplantation: historical and future perspective, Taiwanese Society of Haematology, Taiwan, Guangzhou, China, 11/2010

Vigilance and Surveillance in haematopoietic stem cell transplantation, NOTIFY project meeting, Bologna, Italy, 02/2011

Chronic GvHD: prevention, treatment options and outcomes, European Group for Blood and Marrow Transplantation - THERAKOS Corporate Symposium, Paris, France, 04/2011

The best donor for transplantation, ESH-European Group for Blood and Marrow Transplantation training course, La Baule, France, 05/2011

Donor selection strategies, Southampton and Leeds, United Kingdom, 06/2011

Optimising unrelated donor selection: Development of GIAS, Symposium on Alternative Donor Transplantation: The State of the Art, London, United Kingdom, 02/2012

HSCT: The experiences of registries and future needs, Legal and Ethical Challenges in HSCT, Basel, Switzerland, 03/2012

Impact of stem cell source comparison between peripheral blood and bone marrow: Donor side, Joint WMDA/EBMT session, European Group for Blood and Marrow Transplantation, Geneva, Switzerland, 04/2012

The best donor for transplantation, European School of Haematology - European Group for Blood and Marrow Transplantation training course, Sofia, Bulgaria, 04/2012

A retrospective study of the impact of T cell epitope matching at HLA-DPB1 in recipients of unrelated donor hematopoietic cell transplant Immunobiology Working Group, European Group for Blood and Marrow Transplantation, Geneva, Switzerland, 04/2012

The safety of G-CSF in healthy donors, Chugai Corporate Symposium - European Group for Blood and Marrow Transplantation, Geneva, Switzerland, 04/2012

Adverse events reporting, International Donor Registry Conference, Sydney, Australia, 05/2012

Unrelated donors versus saviour siblings: debate, Science Festival, Aberdeen, United Kingdom, 09/2012

The use of biosimilars in haematology, European Group for Blood and Marrow Transplantation Nurses Group, London, United Kingdom, 10/2012

Biosimilars in paediatric practice, Paediatric Symposium, London, United Kingdom, 10/2012

Are our increasing demands on donors justifiable?, European Group for Blood and Marrow Transplantation, London, United Kingdom, 04/2013

Donor care and management, South African Bone Marrow Donor Registry 21st Anniversary Meeting, Cape Town, South Africa, 09/2013

Donor selection for transplantation, University of Cape Town Bone Marrow Transplant Seminar, Cape Town, South Africa, 09/2013

Donor safety and suitability for transplantation, WBMT/WHO meeting, Brazil, South America, 10/2013

Second allogeneic transplants, British Society of Blood and Marrow Transplantation, London, United Kingdom, 11/2013

What do we know and what should we do about GI toxicity after stem cell transplantation: the role of the gut in GvHD, GI and nutritional consequences of cancer treatment, London, United Kingdom, 11/2013

Donor Issues, European Group for Blood and Marrow Transplantation, Milan, Italy, 03/2014

Patient aspects of transplantation (Medical Basics), World Marrow Donor Association search co-ordinator certification program (Webex), 12/2014

Donor Selection and Safety, Canadian Bone Marrow Group meeting, Montreal, 05/2015

Sorrow Score: HCT-CI, BMT Tandem meeting, Honolulu, 02/2016

How You Can Impact Clinical Practice through Participation: CIBMTR orientation, BMT Tandem meeting, Honolulu, 02/2016

Foundation for the Accreditation of Cellular Therapy (FACT) - JACIE Accreditation in HCT, The 2nd Pujiang Symposium on Immunity and Transplantation, Shanghai, China, 08/2016

Secondary Selection Criteria in Unrelated Donor Transplantation – Including Consideration of DPB1 and other non-HLA Factors, South African Bone Marrow Registry, 2nd Academic Morning, Cape Town, South Africa, 09/2016

Donor Safety and Donor Care vs Patient Needs, Personalized Cancer Immunotherapy Research Oversight Committee Meeting, Quebec, 09/2016

Donor selection according to stem cell source, Panel Discussion: Improving relapse data in registries. 3rd International Workshop on Biology, Prevention and Treatment of Relapse after Stem Cell Transplantation, Hamburg, Germany, 11/2016

CIBMTR-EBMT collaborations in late effects and QOL, EBMT, Marseille, France, 03/2017

Why is haplo-transplantation a success?, WMDA, Minneapolis, MN, 11/2017

CIBMTR: trends in outcomes, 3rd annual 'advancing immunomodulation' meeting., London, UK, 05/2018

The impact of ECP and treatment alternatives on QOL and late effects., The UK ECP patient pathway transformation team meeting, London, UK, 05/2018

Return to work and patient-reported outcomes in CIBMTR, Anthony Nolan survivorship nurses conference, London, UK, 05/2018

Related haploidentical donors versus matched unrelated donors, 22nd Congress of the Brazilian Society of Bone Marrow Transplantation, Rio de Janeiro, Brazil, 08/2018

QOL: How the right choices and complications influence Long term survivors?, 22nd Congress of the Brazilian Society of Bone Marrow Transplantation, Rio de Janeiro, Brazil, 08/2018

HLA and Donor information, 22nd Congress of the Brazilian Society of Bone Marrow Transplantation, Rio de Janeiro, Brazil, 08/2018

State-of-the-art donor selection according to donor secondary characteristics and stem cell source, 22nd Congress of the Brazilian Society of Bone Marrow Transplantation, Rio de Janeiro, Brazil, 08/2018

Survivorship in Hematopoietic Cell Transplant patients- Late effects and quality of life, Winnipeg BMT unit grand rounds, Winnipeg, Canada, 06/2019

HLA and Donor Information, 23rd Congress of the Brazilian Society of Bone Marrow Transplantation, Brasilia, Brazil, 07/2019
Donor Safety and WMDA perspective, 23rd Congress of the Brazilian Society of Bone Marrow Transplantation, Brasilia, Brazil, 07/2019
Late complications after pediatric allogenic Transplants, 23rd Congress of the Brazilian Society of Bone Marrow Transplantation, Brasilia, Brazil, 08/2019
Impact of donor and cell source on relapse after alloHCT, 23rd Congress of the Brazilian Society of Bone Marrow Transplantation, Brasilia, Brazil, 08/2019
Reporting to CIBMTR During the COVID-19 Pandemic, ASTCT & CIBMTR Joint Webinar, Virtual, 04/2020
Promoting donor care, WMDA Virtual Platform, 06/2020
A Stem Cell Donor for Every Patient, Presidential Symposium, American Society of Hematology, Virtual, 12/2020
CIBMTR PRO project, TCT meeting, Virtual, 02/2021
In the absence of a matched-sibling who's the best alternative allogenic donor? A matched unrelated donor, EBMT, Virtual, 03/2021
Do PROs predict HSCT outcome?, Plenary session, EBMT, Virtual, 03/2021
Hematopoietic Cell Transplantation-Comorbidity Index 'Sorrow Score', EBMT, Virtual, 03/2021
Mismatched volunteer unrelated donor, EFI, Virtual, 04/2021
Donor selection: Donor Safety, 2nd Argentine Congress on Hematopoietic Transplantation and Cell Therapy, Virtual, 05/2021
Donor Selection: Non-HLA related factors, 2nd Argentine Congress on Hematopoietic Transplantation and Cell Therapy, Virtual, 05/2021
Mismatched Unrelated Donor Hematopoietic Cell Transplantation: improving outcomes and expanding access, Anthony Nolan Graft selection Day, London, Virtual, 11/2021
Post-transplant cyclophosphamide in MMUD, 5th BMT Transplant Forum, London, UK, 06/2022

CHAIR FOR MEETING SESSIONS:

EBMT, Tandem, EHA, IHWG

INTERNET:

Regular contributions to the Medical Masterclass website of MCQs. Haematology MCQs prepared for MRCP I in the form of a CD rom for Blackwell Science Limited. Now included in Medical Masterclass website/paper modules.

MODERATOR FOR ORAL SESSIONS:

EBMT, ASH, EHA, BSBMT, BMT Tandem

REVIEWER OF MEETING ABSTRACTS:

EBMT, ASH, EHA, BSBMT

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. Somers LJ, **Shaw B**, Lyn BE, McMillan AM, Mahendra P. Meningeal myeloma in the absence of systemic disease, and as the initial feature of disease progression. Clin Lab Haematol. 1998 Jun;20(3):189-90.
2. Paterson PJ, Marshall SR, **Shaw B**, Kendra JR, Ethel M, Kibbler CC, Prentice HG, Potter M. Fatal invasive cerebral Absidia corymbifera infection following bone marrow transplantation. Bone Marrow Transplant. 2000 Sep;26(6):701-3.
3. Chopra R, Eaton JD, Grassi A, Potter M, **Shaw B**, Salat C, Neumeister P, Finazzi G, Iacobelli M, Bowyer K, Prentice HG, Barbui T. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2000 Dec;111(4):1122-9.
4. **Shaw BE**, Perry D, Hoffbrand AV. Progressive arterial thrombosis in a patient with non-Hodgkin's lymphoma, a lupus anticoagulant, factor V Leiden mutation and paraprotein, following chemotherapy. Leuk Lymphoma. 2001 Jun;42(1-2):221-3.
5. **Shaw BE**, Madrigal JA, Potter M. Improving the outcome of unrelated donor stem cell transplantation by

- molecular matching. *Blood Rev.* 2001 Dec;15(4):167-74.
6. **Shaw B**, Mehta AB. Pancytopenia responding to treatment of hyperthyroidism: a clinical case and review of the literature. *Clin Lab Haematol.* 2002 Dec;24(6):385-7.
 7. **Shaw BE**, Potter MN, Mayor NP, Pay AL, Smith C, Goldman JM, Prentice HG, Marsh SG, Madrigal JA. The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and disease relapse following haematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2003 Jun;31(11):1001-8.
 8. **Shaw BE**, Peggs K, Bird JM, Cavenagh J, Hunter A, Alejandro Madrigal J, Russell NH, Sirohi B, Towilson K, Williams CD, Marks DI, Clinical Trials Committee of the British Society of Blood and Marrow Transplantation. The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. *Br J Haematol.* 2003 Dec;123(5):886-95.
 9. **Shaw BE**, Maldonado H, Madrigal JA, Smith C, Petronzelli F, Mayor NP, Potter MN, Bodmer JG, Marsh SG. Polymorphisms in the TNFA gene promoter region show evidence of strong linkage disequilibrium with HLA and are associated with delayed neutrophil engraftment in unrelated donor hematopoietic stem cell transplantation. *Tissue Antigens.* 2004 May;63(5):401-11.
 10. **Shaw BE**, Barber LD, Madrigal JA, Cleaver S, Marsh SG. Scoring for HLA matching? A clinical test of HistoCheck. *Bone Marrow Transplant.* 2004 Aug;34(4):367-8; author reply 369.
 11. Mayor NP, Cox ST, McWhinnie AJ, Argüello JR, **Shaw BE**, Little AM, Madrigal JA, Marsh SG. Sequence of a novel HLA-A*0301 intronic variant (A*03010103). *Tissue Antigens.* 2005 Jan;65(1):107-9.
 12. Kröger N, **Shaw B**, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhäuser M, Ayuk F, Zander AR, Marks DI, Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. *Br J Haematol.* 2005 Jun;129(5):631-43.
 13. Duarte RF, Delgado J, **Shaw BE**, Wrench DJ, Ethell M, Patch D, Dhillon AP, Mackinnon S, Potter MN, Quaglia AF. Histologic features of the liver biopsy predict the clinical outcome for patients with graft-versus-host disease of the liver. *Biol Blood Marrow Transplant.* 2005 Oct;11(10):805-13.
 14. **Shaw BE**, Russell NH, Devereux S, Das-Gupta E, Mackinnon S, Madrigal JA, Pagliuca A, Mufti GJ, Byrne JL. The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors. *Haematologica.* 2005 Nov;90(11):1562-9.
 15. **Shaw BE**, Marsh SG, Mayor NP, Russell NH, Madrigal JA. HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. *Blood.* 2006 Feb 01;107(3):1220-6.
 16. Duarte RF, Pamphilon D, Cornish J, **Shaw BE**, Samson D, Craddock C, Marks D, Mufti GJ, Powles RL, Apperley JF, Madrigal JA, Goldman JM. Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005. *Bone Marrow Transplant.* 2006 May;37(10):901-8.
 17. Bishton MJ, Lush RJ, Byrne JL, Russell NH, **Shaw BE**, Haynes AP. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. *Br J Haematol.* 2007 Mar;136(5):752-61.
 18. **Shaw BE**, Gooley T, Madrigal JA, Malkki M, Marsh SG, Petersdorf EW. Clinical importance of HLA-DPB1 in haematopoietic cell transplantation. *Tissue Antigens.* 2007 Apr;69 Suppl 1:36-41.
 19. **Shaw BE**, Boswell T, Byrne JL, Yates C, Russell NH. Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. *Bone Marrow Transplant.* 2007 May;39(10):623-9.
 20. **Shaw BE**, Byrne JL, Das-Gupta E, Carter GI, Russell NH. The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants. *Biol Blood Marrow Transplant.* 2007 May;13(5):550-9.
 21. Das-Gupta EP, Russell NH, **Shaw BE**, Pearce RM, Byrne JL. Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab. *Biol Blood Marrow Transplant.* 2007 Jun;13(6):724-33.
 22. **Shaw BE**. Practical hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2007 Aug; 40(5):503.
 23. Mayor NP, **Shaw BE**, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, Marsh SG. Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated

- donors. *J Clin Oncol*. 2007 Sep 20;25(27):4262-9.
24. Mayor NP, **Shaw BE**, Keshav S, Madrigal JA, Marsh SG. A novel technique for NOD2/CARD15 genotyping using PCR-SSP. *J Immunol Methods*. 2007 Oct 31;327(1-2):82-7.
 25. **Shaw BE**, Gooley TA, Malkki M, Madrigal JA, Begovich AB, Horowitz MM, Gratwohl A, Ringdén O, Marsh SG, Petersdorf EW. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. *Blood*. 2007 Dec 15;110(13):4560-6.
 26. Mayor NP, **Shaw BE**, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, et al.. In reply: NOD2/CARD15 Polymorphisms in Allogeneic Stem-Cell Transplantation From Unrelated Donors: T Depletion Matters. *J Clin Oncol* 2008; 26(2): 339
 27. Mayor NP, **Shaw BE**, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, Marsh SGE. In reply [6] *Journal of Clinical Oncology*. 10 January 2008;26(2):339.
 28. Madrigal A, **Shaw BE**. Immunogenetic factors in donors and patients that affect the outcome of hematopoietic stem cell transplantation. *Blood Cells Mol Dis*. 2008;40(1):40-3.
 29. **Shaw BE**, Russell NH. Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. *Bone Marrow Transplant*. 2008 Mar;41(5):495-503.
 30. Ingram W, Devereux S, Das-Gupta EP, Russell NH, Haynes AP, Byrne JL, **Shaw BE**, McMillan A, Gonzalez J, Ho A, Mufti GJ, Pagliuca A. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. *Br J Haematol*. 2008 Apr;141(2):235-43.
 31. Tholouli E, Liakopoulou E, Greenfield HM, **Shaw BE**, Tauro S, Byrne JL, Dennis M, Burthem J, Lucas GS, Craddock C, Russell NH, Liu Yin JA. Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. *Br J Haematol*. 2008 Jun;142(2):318-20.
 32. **Shaw BE**. The clinical implications of HLA mismatches in unrelated donor haematopoietic cell transplantation. *Int J Immunogenet*. 2008 Aug;35(4-5):367-74.
 33. **Shaw BE**, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towson KE, Apperley JF, Chakraverty R, Craddock CF, Kazmi MA, Littlewood TJ, Milligan DW, Pagliuca A, Thomson KJ, Marks DI, Russell NH. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. *Bone Marrow Transplant*. 2008 Dec;42(12):783-9.
 34. Mayor NP, **Shaw BE**, Madrigal JA, Marsh SG. No impact of NOD2/CARD15 on outcome after SCT: a reply. *Bone Marrow Transplant*. 2008 Dec;42(12):837-8.
 35. Srikanth M, Davies FE, Wu P, Jenner MW, Ethell ME, Potter MN, **Shaw BE**, Saso RM, Dines S, Morgan GJ. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. *Eur J Haematol*. 2008 Dec;81(6):432-6.
 36. **Shaw BE**. Human leukocyte antigen matching, compatibility testing and donor selection Hematopoietic Stem Cell Transplantation in Clinical Practice. 2009:239-247.
 37. Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, Potter MN, Ethell ME, **Shaw BE**, Morgan GJ. The impact of extramedullary disease at presentation on the outcome of myeloma. *Leuk Lymphoma*. 2009 Feb;50(2):230-5.
 38. Querol S, Mufti GJ, Marsh SG, Pagliuca A, Little AM, **Shaw BE**, Jeffery R, Garcia J, Goldman JM, Madrigal JA. Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be? *Haematologica*. 2009 Apr;94(4):536-41. PMID: PMC2663617
 39. **Shaw BE**, Veys P, Pagliuca A, Addada J, Cook G, Craddock CF, Gennery AR, Goldman J, Mackinnon S, Madrigal JA, Marks DI, Navarrete C, Potter MN, Querol S, Regan F, Russell NH, Hough RE. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms. *Bone Marrow Transplant*. 2009 Jul;44(1):7-12.
 40. Dignan FL, Evans SO, Ethell ME, **Shaw BE**, Davies FE, Dearden CE, Treleaven JG, Riley UB, Morgan GJ, Potter MN. An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. *Bone Marrow Transplant*. 2009 Jul;44(1):51-6.
 41. Tulpule S, **Shaw BE**, Makoni P, Little AM, Madrigal JA, Goldman JM. Severe allergic reaction with anaphylaxis to G-CSF (lenograstim) in a healthy donor. *Bone Marrow Transplant*. 2009 Jul;44(2):129-30.
 42. Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, Craddock C, Liakopoulou E, Fielding AK, Mackinnon S, Olavarria E, Potter MN, Russell NH, **Shaw BE**, Cook G, Goldstone AH, Marks DI.

- Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. *Haematologica*. 2009 Oct;94(10):1399-406. PMID: PMC2754956
43. **Shaw BE**, Mayor NP, Russell NH, Apperley JF, Clark RE, Cornish J, Darbyshire P, Ethell ME, Goldman JM, Little AM, Mackinnon S, Marks DI, Pagliuca A, Thomson K, Marsh SG, Madrigal JA. Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. *Leukemia*. 2010 Jan;24(1):58-65.
 44. Berro M, Mayor NP, Maldonado-Torres H, Cooke L, Kusminsky G, Marsh SG, Madrigal JA, **Shaw BE**. Association of functional polymorphisms of the transforming growth factor B1 gene with survival and graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation. *Haematologica*. 2010 Feb;95(2):276-83. PMID: PMC2817031
 45. **Shaw BE**, Ball L, Beksac M, Bengtsson M, Confer D, Diler S, Fechter M, Greinix H, Koh M, Lee S, Nicoloso-De-Faveri G, Philippe J, Pollichieni S, Pulsipher M, Schmidt A, Yang E, van Walraven AM, Clinical Working Group, Ethics Working Group of the WMDA. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. *Bone Marrow Transplant*. 2010 May;45(5):832-8.
 46. **Shaw BE**. First do no harm. *Blood*. 2010 Jun 17;115(24):4978-9.
 47. van Walraven SM, Nicoloso-de Faveri G, Axdorph-Nygell UA, Douglas KW, Jones DA, Lee SJ, Pulsipher M, Ritchie L, Halter J, **Shaw BE**, WMDA Ethics and Clinical working groups. Family donor care management: principles and recommendations. *Bone Marrow Transplant*. 2010 Aug;45(8):1269-73.
 48. **Shaw BE**, Arguello R, Garcia-Sepulveda CA, Madrigal JA. The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. *Br J Haematol*. 2010 Aug;150(3):251-8.
 49. Boo M, van Walraven SM, Chapman J, Lindberg B, Schmidt AH, **Shaw BE**, Switzer GE, Yang E, Egeland T, World Marrow Donor Association. Remuneration of hematopoietic stem cell donors: principles and perspective of the World Marrow Donor Association. *Blood*. 2011 Jan 06;117(1):21-5.
 50. King RJ, Confer DL, Greinix HT, Halter J, Horowitz M, Schmidt AH, Costeas P, **Shaw B**, Egeland T, Ethics and Clinical Working Groups of World Marrow Donor Association. Unrelated hematopoietic stem cell donors as research subjects. *Bone Marrow Transplant*. 2011 Jan;46(1):10-3.
 51. Duarte RF, **Shaw BE**, Marín P, Kottaridis P, Ortiz M, Morante C, Delgado J, Gayoso J, Goterriz R, Martínez-Chamorro C, Mateos-Mazón JJ, Ramírez C, de la Rubia J, Achtereekte H, Gandhi PJ, Douglas KW, Russell NH. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. *Bone Marrow Transplant*. 2011 Jan;46(1):52-8.
 52. Kanga U, McWhinnie AJ, Mourya M, **Shaw BE**, Madrigal JA, Mehra NK. A novel HLA-DPB1 allele, DPB1*125:01, identified by sequence-based typing in an Indian individual. *Tissue Antigens*. 2011 Jan;77(1):85-7.
 53. Mohammed K, Dignan F, Ethell ME, Davies FE, Morgan GJ, Riley U, Evans S, Potter MN, **Shaw BE**. An early computed tomography-guided antifungal treatment strategy is safe and efficacious in patients undergoing chemotherapy for high-risk acute leukemia. *Leuk Lymphoma*. 2011 Feb;52(2):339-40.
 54. Hiwarkar P, **Shaw BE**, Tredger JM, Brown NW, Kulkarni S, Saso R, Evans S, Treleaven J, Davies FE, Ethell ME, Morgan GJ, Potter MN. Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin. *Clin Transplant*. 2011;25(2):222-7.
 55. **Shaw BE**, Apperley JF, Russell NH, Craddock C, Liakopoulou E, Potter MN, Wynn R, Gibson B, Pearce RM, Kirkland K, Lee J, Madrigal JA, Cook G, Byrne JL. Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. *Br J Haematol*. 2011 Apr;153(2):244-52.
 56. Anoop P, **Shaw BE**, Riley U, Ethell ME, Taj M, Lancaster DL, Atra A, Saso R, Littlewood S, Mohammed K, Davies F, Treleaven J, Morgan GJ, Potter MN. Clinical profile and outcome of urotheliotropic viral haemorrhagic cystitis following haematopoietic stem cell transplantation: a 7-year tertiary centre analysis. *Hematology*. 2011 Jul;16(4):213-20.
 57. **Shaw BE**, Confer DL, Hwang WY, Pamphilon DH, Pulsipher MA. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. *Haematologica*. 2011 Jul;96(7):942-7. PMID: PMC3128211
 58. Confer DL, **Shaw BE**, Pamphilon DH, Clinical Working Group of the WMDA. WMDA guidelines for subsequent donations following initial BM or PBSCs. *Bone Marrow Transplant*. 2011

- Nov;46(11):1409-12.
59. Arrieta-Bolaños E, Madrigal JA, **Shaw BE**. Human leukocyte antigen profiles of latin american populations: differential admixture and its potential impact on hematopoietic stem cell transplantation. *Bone Marrow Res.* 2012;2012:136087. PMID: PMC3506882
 60. Mayor NP, **Shaw BE**, Madrigal JA, Marsh SG. NOD2 Polymorphisms and Their Impact on Haematopoietic Stem Cell Transplant Outcome. *Bone Marrow Res.* 2012;2012:180391. PMID: PMC3483648
 61. Lange A, Raffoux C, **Shaw B**. Biological and Genetic Aspects of Donor-Recipient Matching in HSCT. *Bone Marrow Res.* 2012;2012:212593. PMID: PMC3523404
 62. Fleischhauer K, **Shaw BE**, Gooley T, Malkki M, Bardy P, Bignon JD, Dubois V, Horowitz MM, Madrigal JA, Morishima Y, Oudshoorn M, Ringden O, Spellman S, Velardi A, Zino E, Petersdorf EW, International Histocompatibility Working Group in Hematopoietic Cell Transplantation. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. *Lancet Oncol.* 2012 Apr;13(4):366-74. PMID: PMC3813000
 63. Lown RN, **Shaw BE**. 'First do no harm': where do we stand on unrelated hematopoietic cell donor safety? *Expert Rev Hematol.* 2012 Jun;5(3):249-52.
 64. Arrieta-Bolaños E, Madrigal JA, **Shaw BE**. Transforming growth factor- β 1 polymorphisms and the outcome of hematopoietic stem cell transplantation. *Int J Immunogenet.* 2012 Jun;39(3):192-202.
 65. Dignan FL, Greenblatt D, Cox M, Cavenagh J, Oakervee H, Apperley JF, Fielding AK, Pagliuca A, Mufti G, Raj K, Marks DI, Amrolia P, Peniket A, Medd P, Potter MN, **Shaw BE**, Scarisbrick JJ. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. *Bone Marrow Transplant.* 2012 Jun;47(6):824-30.
 66. Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P, Scarisbrick JJ, Taylor PC, Hadzic N, **Shaw BE**, Potter MN, Haemato-oncology Task Force of British Committee for Standards in Haematology, British Society for Blood and Marrow Transplantation. Diagnosis and management of acute graft-versus-host disease. *Br J Haematol.* 2012 Jul;158(1):30-45.
 67. Dignan FL, Amrolia P, Clark A, Cornish J, Jackson G, Mahendra P, Scarisbrick JJ, Taylor PC, **Shaw BE**, Potter MN, Haemato-oncology Task Force of British Committee for Standards in Haematology, British Society for Blood and Marrow Transplantation. Diagnosis and management of chronic graft-versus-host disease. *Br J Haematol.* 2012 Jul;158(1):46-61.
 68. Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, Jackson G, Mahendra P, Taylor PC, Shah P, Lightman S, Fortune F, Kibbler C, Andreyev J, Albanese A, Hadzic N, Potter MN, **Shaw BE**, Haemato-oncology Task Force of British Committee for Standards in Haematology, British Society for Blood and Marrow Transplantation. Organ-specific management and supportive care in chronic graft-versus-host disease. *Br J Haematol.* 2012 Jul;158(1):62-78.
 69. Hollenbach JA, Madbouly A, Gragert L, Vierra-Green C, Fleisch S, Spellman S, Begovich A, Noreen H, Trachtenberg E, Williams T, Yu N, **Shaw B**, Fleischhauer K, Fernandez-Vina M, Maiers M. A combined DPA1~DPB1 amino acid epitope is the primary unit of selection on the HLA-DP heterodimer. *Immunogenetics.* 2012 Aug;64(8):559-69. PMID: PMC3395342
 70. Pulsipher MA, Chitphakdithai P, Logan BR, **Shaw BE**, Wingard JR, Lazarus HM, Waller EK, Seftel M, Stroncek DF, Lopez AM, Maharaj D, Hematti P, O'Donnell PV, Loren AW, Leitman SF, Anderlini P, Goldstein SC, Levine JE, Navarro WH, Miller JP, Confer DL. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. *Blood.* 2013 Jan 03;121(1):197-206. PMID: PMC3538330
 71. **Shaw BE**, Nolan A. Allogeneic transplantation: when is a mismatch better than a match? *Biol Blood Marrow Transplant.* 2013 Jan;19(1):1-2.
 72. Dignan FL, Manwani R, Potter MN, Ethell ME, Leonard H, Brennan J, Baker J, **Shaw BE**. A dedicated GvHD clinic may improve the quality of life for allogeneic stem cell transplant survivors. *Clin Transplant.* 2013;27(1):E1-2.
 73. Dignan FL, Potter MN, Ethell ME, Taylor M, Lewis L, Brennan J, McNamara L, Evans SO, Riley U, Davies FE, Dearden CE, Morgan GJ, **Shaw BE**. High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD. *Clin Transplant.* 2013;27(1):E56-63.
 74. Petersdorf EW, Malkki M, Hsu K, Bardy P, Cesbron A, Dickinson A, Dubois V, Fleischhauer K, Kawase T, Madrigal A, Morishima Y, **Shaw B**, Spellman S, Spierings E, Stern M, Tiercy JM, Velardi A, Gooley T, International Histocompatibility Working Group in Hematopoietic Cell Transplantation. 16th IHIW: international histocompatibility working group in hematopoietic cell transplantation. *Int J Immunogenet.* 2013 Feb;40(1):2-10. PMID: PMC3887040

75. Halter JP, van Walraven SM, Worel N, Bengtsson M, Häggglund H, Nicoloso de Faveri G, **Shaw BE**, Schmidt AH, Fechter M, Madrigal A, Szer J, Aljurf MD, Weisdorf D, Horowitz MM, Greinix H, Niederwieser D, Gratwohl A, Kodera Y, Confer D. Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). *Bone Marrow Transplant.* 2013 Feb;48(2):220-5.
76. Lown RN, **Shaw BE**. Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision. *Bone Marrow Transplant.* 2013 Feb;48(2):210-9.
77. Medd PG, Peniket AJ, Littlewood TJ, Pearce R, Perry J, Kirkland KE, **Shaw BE**, Potter MN, Craddock CF, Milligan DW, Fielding AK, Marks DI, Cook G, British Society of Blood and Marrow Transplantation. Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study. *Bone Marrow Transplant.* 2013 Jul;48(7):982-7.
78. Medd PG, Peniket AJ, Littlewood TJ, Pearce R, Perry J, Kirkland KE, **Shaw BE**, Potter MN, Craddock CF, Milligan DW, Fielding AK, Marks DI, Cook G. Erratum: Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: A British Society of Blood and Marrow Transplantation study (*Bone Marrow Transplantation* (2013) 48 (982-987) DOI: 10.1038/bmt.2012.261) *Bone Marrow Transplantation.* October 2013;48(10):1368.
79. **Shaw BE**, Chapman J, Fechter M, Foeken L, Greinix H, Hwang W, Phillips-Johnson L, Korhonen M, Lindberg B, Navarro WH, Szer J. Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation. *Bone Marrow Transplant.* 2013 Nov;48(12):1506-9.
80. **Shaw BE**, Robinson J, Fleischhauer K, Madrigal JA, Marsh SG. Translating the HLA-DPB1 T-cell epitope-matching algorithm into clinical practice. *Bone Marrow Transplant.* 2013 Nov;48(12):1510-2.
81. Lown RN, Tulpule S, Russell NH, Craddock CF, Roest R, Madrigal JA, **Shaw BE**. Subsequent donation requests among 2472 unrelated hematopoietic progenitor cell donors are associated with bone marrow harvest. *Haematologica.* 2013 Dec;98(12):1956-63. PMID: PMC3856971
82. Lee F, Luevano M, Veys P, Yong K, Madrigal A, **Shaw BE**, Saudemont A. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface. *PLoS One.* 2014;9(7):e103254. PMID: PMC4106894
83. Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, Marks DI, Jackson B, Chakupurakal G, Dennis M, Lim Z, Cook G, Carpenter B, Pettitt AR, Mathew S, Connelly-Smith L, Yin JA, Viskaduraki M, Chakraverty R, Orchard K, **Shaw BE**, Byrne JL, Brookes C, Craddock CF, Chaganti S. EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. *Bone Marrow Transplant.* 2014 Feb;49(2):280-6.
84. Lown RN, Marsh SG, Switzer GE, Latham KA, Madrigal JA, **Shaw BE**. Ethnicity, length of time on the register and sex predict donor availability at the confirmatory typing stage. *Bone Marrow Transplant.* 2014 Apr;49(4):525-31.
85. Anthias C, Dignan FL, Morilla R, Morilla A, Ethell ME, Potter MN, **Shaw BE**. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. *Bone Marrow Transplant.* 2014 May;49(5):679-83.
86. Dignan FL, Aguilar S, Scarisbrick JJ, **Shaw BE**, Potter MN, Cavenagh J, Apperley JF, Fielding AK, Pagliuca A, Raj K, Marks DI, Peniket A, Crawley C, Koh MB, Child FJ. Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD. *Bone Marrow Transplant.* 2014 May;49(5):704-8.
87. Billen A, Madrigal JA, **Shaw BE**. A review of the haematopoietic stem cell donation experience: is there room for improvement? *Bone Marrow Transplant.* 2014 Jun;49(6):729-36.
88. Pulsipher MA, Chitphakdithai P, Logan BR, Navarro WH, Levine JE, Miller JP, **Shaw BE**, O'Donnell PV, Majhail NS, Confer DL. Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. *Blood.* 2014 Jun 05;123(23):3655-63. PMID: PMC4047500
89. Lown RN, Philippe J, Navarro W, van Walraven SM, Philips-Johnson L, Fechter M, Pawson R, Bengtsson M, Beksac M, Field S, Yang H, **Shaw BE**, World Marrow Donor Association Clinical Working Group Committee. Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee. *Bone Marrow Transplant.* 2014 Jul;49(7):880-6.
90. Fleischhauer K, Fernandez-Viña MA, Wang T, Haagenson M, Battiwalla M, Baxter-Lowe LA, Ciceri F, Dehn J, Gajewski J, Hale GA, Heemskerk MB, Marino SR, McCarthy PL, Miklos D, Oudshoorn M, Pollack MS, Reddy V, Senitzer D, **Shaw BE**, Waller EK, Lee SJ, Spellman SR. Risk associations

- between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1. *Bone Marrow Transplant.* 2014 Sep;49(9):1176-83. PMID: PMC4154997
91. Das-Gupta E, Dignan F, **Shaw B**, Raj K, Malladi R, Gennery A, Bonney D, Taylor P, Scarisbrick J. Extracorporeal photopheresis for treatment of adults and children with acute GVHD: UK consensus statement and review of published literature. *Bone Marrow Transplant.* 2014 Oct;49(10):1251-8.
 92. Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, Askar M, Dehn J, Fernandez Viña M, Gratwohl A, Gupta V, Hanna R, Horowitz MM, Hurley CK, Inamoto Y, Kassim AA, Nishihori T, Mueller C, Oudshoorn M, Petersdorf EW, Prasad V, Robinson J, Saber W, Schultz KR, **Shaw B**, Storek J, Wood WA, Woolfrey AE, Anasetti C. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. *Blood.* 2014 Oct 16;124(16):2596-606. PMID: PMC4199961
 93. Arrieta-Bolaños E, Madrigal JA, Marsh SG, **Shaw BE**, Salazar-Sánchez L. The frequency of HLA-B(?)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica. *Hum Immunol.* 2014 Nov;75(11):1092-6.
 94. Billen A, Madrigal JA, Szydlo RM, **Shaw BE**. Female donors and donors who are lighter than their recipient are less likely to meet the CD34+ cell dose requested for peripheral blood stem cell transplantation. *Transfusion.* 2014 Nov;54(11):2953-60.
 95. Feliu J, Clay J, Raj K, Barber L, Devlia V, **Shaw B**, Pagliuca A, Mufti G. Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies. *Br J Haematol.* 2014 Nov;167(3):426-8.
 96. Arrieta-Bolaños E, McWhinnie AJ, Madrigal-Sánchez JJ, Calvo L, Salazar-Sánchez L, Madrigal JA, Marsh SG, **Shaw BE**. A novel HLA-A allele, A*74:23, identified in an individual from Costa Rica. *Tissue Antigens.* 2014 Dec;84(6):583-4.
 97. Srisankarajah P, Webb K, Chisholm D, Raobaikady R, Davis K, Pepper N, Ethell ME, Potter MN, **Shaw BE**. Retrospective cohort analysis comparing the incidence of deep vein thromboses between peripherally-inserted and long-term skin tunneled venous catheters in hemato-oncology patients. *Thromb J.* 2015;13:21. PMID: PMC4480444
 98. Hsu JW, Wingard JR, Logan BR, Chitphakdithai P, Akpek G, Anderlini P, Artz AS, Bredeson C, Goldstein S, Hale G, Hematti P, Joshi S, Kamble RT, Lazarus HM, O'Donnell PV, Pulsipher MA, Savani BN, Schears RM, **Shaw BE**, Confer DL. Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis. *Biol Blood Marrow Transplant.* 2015 Jan;21(1):165-71. PMID: PMC4272878
 99. Scarisbrick JJ, Dignan FL, Tulpule S, Gupta ED, Kolade S, **Shaw B**, Evison F, Shah G, Tholouli E, Mufti G, Pagliuca A, Malladi R, Raj K. A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent. *Bone Marrow Transplant.* 2015 Jan;50(1):62-7.
 100. Nikolousis E, Nagra S, Pearce R, Perry J, Kirkland K, Byrne J, Dignan F, Tholouli E, Gilleece M, Russell N, Littlewood T, Cook M, Peniket A, **Shaw BE**, Cook G, Craddock C. Impact of pre-transplant comorbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study. *Bone Marrow Transplant.* 2015 Jan;50(1):82-6.
 101. **Shaw BE**, Lee F, Krishnamurthy S, Byrne JL, Seedhouse C, Mayor NP, Maldonado-Torres H, Saudemont A, Marsh SG, Madrigal JA, Russell NH. Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation. *Bone Marrow Transplant.* 2015 Feb;50(2):237-43.
 102. Anthias C, Ethell ME, Potter MN, Madrigal A, **Shaw BE**. The impact of improved JACIE standards on the care of related BM and PBSC donors. *Bone Marrow Transplant.* 2015 Feb;50(2):244-7.
 103. Billen A, Madrigal JA, Strydom A, Szydlo RM, Switzer GE, **Shaw BE**. Predonation health-related quality of life scores predict time to recovery in hematopoietic stem cell donors. *Biol Blood Marrow Transplant.* 2015 Feb;21(2):350-6.
 104. **Shaw BE**, Confer DL, Hwang W, Pulsipher MA. A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies. *Bone Marrow Transplant.* 2015 Mar;50(3):334-40.
 105. Anthias C, van Walraven SM, Sørensen BS, de Faveri GN, Fechter M, Cornish J, Bacigalupo A, Müller C, Boo M, **Shaw BE**. Related hematopoietic cell donor care: is there a role for unrelated donor registries? *Bone Marrow Transplant.* 2015 May;50(5):637-41.

106. Arrieta-Bolaños E, Madrigal JA, **Shaw BE**. Novel alleles of the transforming growth factor β -1 regulatory region and exon 1. *Tissue Antigens*. 2015 Jun;85(6):484-91.
107. Inamoto Y, Shah NN, Savani BN, **Shaw BE**, Abraham AA, Ahmed IA, Akpek G, Atsuta Y, Baker KS, Basak GW, Bitan M, DeFilipp Z, Gregory TK, Greinix HT, Hamadani M, Hamilton BK, Hayashi RJ, Jacobsohn DA, Kamble RT, Kasow KA, Khera N, Lazarus HM, Malone AK, Lupo-Stanghellini MT, Margossian SP, Muffly LS, Norkin M, Ramanathan M, Salooja N, Schoemans H, Wingard JR, Wirk B, Wood WA, Yong A, Duncan CN, Flowers ME, Majhail NS. Secondary solid cancer screening following hematopoietic cell transplantation. *Bone Marrow Transplant*. 2015 Aug;50(8):1013-23. PMID: PMC4989866
108. **Shaw BE**, Logan BR, Kiefer DM, Chitphakdithai P, Pedersen TL, Abdel-Azim H, Abidi MH, Akpek G, Diaz MA, Artz AS, Dandoy C, Gajewski JL, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Majhail NS, O'Donnell PV, Olsson RF, Savani BN, Schears RM, Stroncek DF, Switzer GE, Williams EP, Wingard JR, Wirk BM, Confer DL, Pulsipher MA. Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. *Biol Blood Marrow Transplant*. 2015 Oct;21(10):1830-8. PMID: PMC4568129
109. Booth GS, Gehrie EA, Jagasia MH, **Shaw BE**, Savani BN. When Can You Discard Stem Cells? *Biol Blood Marrow Transplant*. 2015 Nov;21(11):2033.
110. Li Z, Mewawalla P, Stratton P, Yong AS, **Shaw BE**, Hashmi S, Jagasia M, Mohty M, Majhail NS, Savani BN, Rovó A. Sexual health in hematopoietic stem cell transplant recipients. *Cancer*. 2015 Dec 01;121(23):4124-31. PMID: PMC5014908
111. Ehrhardt MJ, Brazauskas R, He W, Rizzo JD, **Shaw BE**. Survival of patients who develop solid tumors following hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2016 Jan;51(1):83-8. PMID: PMC4570237
112. Bitan M, van Walraven SM, Worel N, Ball LM, Styczynski J, Torrabadella M, Witt V, **Shaw BE**, Seber A, Yabe H, Greinix HT, Peters C, Gluckman E, Rocha V, Halter J, Pulsipher MA. Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association. *Biol Blood Marrow Transplant*. 2016 Jan;22(1):96-103.
113. Lee JB, Billen A, Lown RN, Potter MN, Craddock CF, de Lavallade H, **Shaw BE**, Sharpe CC. Exacerbation of IgA nephropathy following G-CSF administration for PBSC collection: suggestions for better donor screening. *Bone Marrow Transplant*. 2016 Feb;51(2):286-7.
114. Hough R, Danby R, Russell N, Marks D, Veys P, **Shaw B**, Wynn R, Vora A, Mackinnon S, Peggs KS, Crawley C, Craddock C, Pagliuca A, Cook G, Snowden JA, Clark A, Marsh J, Querol S, Parkes G, Braund H, Rocha V. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. *Br J Haematol*. 2016 Feb;172(3):360-70.
115. Snowden JA, Danby R, Ruggeri A, Marks DI, Hough RE, Pagliuca A, Potter M, Russell N, Craddock C, Clark A, Miller P, Cook G, Gluckman E, **Shaw BE**, Rocha V. Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the UK National Health Service : a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord. *Br J Haematol*. 2016 Feb;172(3):478-81.
116. Anthias C, O'Donnell PV, Kiefer DM, Yared J, Norkin M, Anderlini P, Savani BN, Diaz MA, Bitan M, Halter JP, Logan BR, Switzer GE, Pulsipher MA, Confer DL, **Shaw BE**. European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care Standards. *Biol Blood Marrow Transplant*. 2016 Mar;22(3):514-9. PMID: PMC4760354
117. Anthias C, **Shaw BE**, Kiefer DM, Liesveld JL, Yared J, Kamble RT, D'Souza A, Hematti P, Seftel MD, Norkin M, DeFilipp Z, Kasow KA, Abidi MH, Savani BN, Shah NN, Anderlini P, Diaz MA, Malone AK, Halter JP, Lazarus HM, Logan BR, Switzer GE, Pulsipher MA, Confer DL, O'Donnell PV. Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. *Biol Blood Marrow Transplant*. 2016 Mar;22(3):520-7. PMID: PMC4760616
118. Arrieta-Bolaños E, Mayor NP, Marsh SG, Madrigal JA, Apperley JF, Kirkland K, Mackinnon S, Marks DI, McQuaker G, Perry J, Potter MN, Russell NH, Thomson K, **Shaw BE**. Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors. *Haematologica*. 2016 Mar;101(3):382-90. PMID: PMC4815730
119. Dignan FL, Clark A, Aitken C, Gilleece M, Jayakar V, Krishnamurthy P, Pagliuca A, Potter MN, **Shaw B**,

- Skinner R, Turner A, Wynn RF, Coyle P, Haemato-oncology Task Force of the British Committee for Standards in Haematology, British Society for Blood and Marrow Transplantation and the UK Clinical Virology Network. BCSH/BSBMT/UK clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. *Br J Haematol*. 2016 May;173(3):380-93. PMID: PMC7161808
120. Anthias C, Billen A, Arkwright R, Szydlo RM, Madrigal JA, **Shaw BE**. Harvests from bone marrow donors who weigh less than their recipients are associated with a significantly increased probability of a suboptimal harvest yield. *Transfusion*. 2016 May;56(5):1052-7.
 121. Szer J, Elmoazzen H, Fechter M, Hwang W, Korhonen M, Miller J, Mengling T, **Shaw B**, Stein J. Safety of Living Donation of Hematopoietic Stem Cells. *Transplantation*. 2016 Jun;100(6):1329-31.
 122. Sorensen BS, Szer J, **Shaw B**, Korhonen M, Mengling T, Fechter M, Elmoazzen H, Lindberg B, Chapman J, Nørgaard JM, Foeken L, Hwang WY, Nielsen B. Inadvertent completely HLA-mismatched allogeneic unrelated bone marrow transplant: lessons learned. *Bone Marrow Transplant*. 2016 Jul;51(7):1016-8.
 123. Li Z, Rubinstein SM, Thota R, Savani M, Brissot E, **Shaw BE**, Majhail NS, Mohty M, Savani BN. Immune-Mediated Complications after Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2016 Aug;22(8):1368-1375.
 124. DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers MED, Savani BN, **Shaw BE**, CIBMTR Late Effects and Quality of Life Working Committee, EBMT Complications and Quality of Life Working Party. Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. *Biol Blood Marrow Transplant*. 2016 Aug;22(8):1493-1503. PMID: PMC4949101
 125. **Shaw BE**, Lee SJ, Horowitz MM, Wood WA, Rizzo JD, Flynn KE. Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN. *Bone Marrow Transplant*. 2016 Sep;51(9):1173-9.
 126. Switzer GE, Bruce J, Kiefer DM, Kobusingye H, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, **Shaw BE**, van Walraven SM, Wiener L, Packman W, Varni JW, Pulsipher MA. Health-Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors. *J Pediatr*. 2016 Nov;178:164-170.e1. PMID: PMC5085860
 127. Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, **Shaw BE**, Rizzo JD, Drobyski W, Hamadani M. Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. *Bone Marrow Transplant*. 2016 Dec;51(12):1602-1604.
 128. Anthias C, Peniket A, Kirkland K, Madrigal JA, **Shaw BE**. Variations in practice in UK transplant centers: results of a related donor care survey. *Bone Marrow Transplant*. 2016 Dec;51(12):1612-1614.
 129. Lee SJ, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, Waller EK, Maziarz RT, Wu J, **Shaw BE**, Confer D, Horowitz MM, Anasetti C. Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. *JAMA Oncol*. 2016 Dec 01;2(12):1583-1589. PMID: PMC5145732
 130. Switzer GE, Bruce J, Kiefer DM, Kobusingye H, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, **Shaw BE**, Riches M, Hayes-Lattin B, Linenberger M, Bolwell B, Rowley SD, Litzow MR, Pulsipher MA. Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study. *Biol Blood Marrow Transplant*. 2017 Jan;23(1):165-171. PMID: PMC5182103
 131. **Shaw BE**, Hahn T, Martin PJ, Mitchell SA, Petersdorf EW, Armstrong GT, Shelburne N, Storer BE, Bhatia S. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. *Biol Blood Marrow Transplant*. 2017 Jan;23(1):10-23. PMID: PMC5182148
 132. DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P,

- Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers ME, Savani BN, **Shaw BE**. Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. *Bone Marrow Transplant*. 2017 Feb;52(2):173-182. PMID: PMC5288134
133. **Shaw BE**. Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint. *Blood Adv*. 2017 Feb 14;1(6):401-406. PMID: PMC5738987
134. Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, **Shaw BE**, Beato F, Laport GG, Nademane A, Keating A, Socie G, Anasetti C. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2017 Mar;23(3):405-411. PMID: PMC6716167
135. **Shaw BE**, Mayor NP, Szydlo RM, Bultitude WP, Anthias C, Kirkland K, Perry J, Clark A, Mackinnon S, Marks DI, Pagliuca A, Potter MN, Russell NH, Thomson K, Madrigal JA, Marsh SGE. Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants. *Bone Marrow Transplant*. 2017 May;52(5):717-725.
136. Berro M, Palau Nagore MV, Rivas MM, Longo P, Foncuberta C, Vitriú A, Remaggi G, Martínez Rolon J, Jaimovich G, Requejo A, Feldman L, Padros K, Rodríguez MB, **Shaw BE**, Larripa I, Belli CB, Kusminsky GD. Transforming growth factor- β 1 functional polymorphisms in myeloablative sibling hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2017 May;52(5):739-744.
137. Hamblin A, Greenfield DM, Gilleece M, Salooja N, Kenyon M, Morris E, Glover N, Miller P, Braund H, Peniket A, **Shaw BE**, Snowden JA. Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes. *Bone Marrow Transplant*. 2017 Jun;52(6):889-894.
138. Gabriel M, **Shaw BE**, Brazauskas R, Chen M, Margolis DA, Sengelov H, Dahlberg A, Ahmed IA, Delgado D, Lazarus HM, Gibson B, Myers KC, Kamble RT, Abdel-Mageed A, Li CK, Flowers MED, Battiwalla M, Savani BN, Majhail N, Shaw PJ. Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR). *Biol Blood Marrow Transplant*. 2017 Aug;23(8):1320-1326. PMID: PMC5518678
139. Vrooman LM, Millard HR, Brazauskas R, Majhail NS, Battiwalla M, Flowers ME, Savani BN, Akpek G, Aljurf M, Bajwa R, Baker KS, Beitinjaneh A, Bitan M, Buchbinder D, Chow E, Dandoy C, Dietz AC, Diller L, Gale RP, Hashmi SK, Hayashi RJ, Hematti P, Kamble RT, Kasow KA, Kletzel M, Lazarus HM, Malone AK, Marks DI, O'Brien TA, Olsson RF, Ringden O, Seo S, Steinberg A, Yu LC, Warwick A, **Shaw B**, Duncan C. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. *Biol Blood Marrow Transplant*. 2017 Aug;23(8):1327-1334. PMID: PMC5666571
140. Fleischhauer K, **Shaw BE**. HLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities. *Blood*. 2017 Aug 31;130(9):1089-1096.
141. Switzer GE, Bruce J, Pastorek G, Kiefer DM, Kobusingye H, Drexler R, Besser RAM, Confer DL, Horowitz MM, King RJ, **Shaw BE**, van Walraven SM, Wiener L, Packman W, Varni JW, Pulsipher MA. Parent versus child donor perceptions of the bone marrow donation experience. *Bone Marrow Transplant*. 2017 Sep;52(9):1338-1341. PMID: PMC5933883
142. Fleischhauer K, Ahn KW, Wang HL, Zito L, Crivello P, Müller C, Verneris M, **Shaw BE**, Pidala J, Oudshorn M, Lee SJ, Spellman SR. Directionality of non-permissive HLA-DPB1 T-cell epitope group mismatches does not improve clinical risk stratification in 8/8 matched unrelated donor hematopoietic cell transplantation. *Bone Marrow Transplant*. 2017 Sep;52(9):1280-1287. PMID: PMC5968827
143. Jerkins JH, Hamadani M, Zook F, Epperla N, **Shaw BE**, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN. Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. *Am J Hematol*. 2017 Oct;92(10):E610-E611.
144. Berro M, Arbelbide JA, Rivas MM, Basquiera AL, Ferini G, Vitriú A, Foncuberta C, Fernandez Escobar N, Requejo A, Milovic V, Yantorno S, Szelagoswki M, Martinez Rolon J, Bentolila G, Garcia JJ, Garcia P, Caeiro G, Castro M, Jaimovich G, Palmer S, Trucco JI, Bet LA, **Shaw BE**, Kusminsky GD. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2017 Oct;23(10):1646-1650.
145. Billen A, Madrigal JA, Scior K, **Shaw BE**, Strydom A. Donation of peripheral blood stem cells to unrelated strangers: A thematic analysis. *PLoS One*. 2017;12(10):e0186438. PMID: PMC5656410

146. Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, **Shaw BE**, Shahir K, Banerjee A, Drobyski WR. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. *Biol Blood Marrow Transplant*. 2017 Nov;23(11):1955-1960.
147. **Shaw BE**, Brazauskas R, Millard HR, Fonstad R, Flynn KE, Abernethy A, Vogel J, Petroske C, Mattila D, Drexler R, Lee SJ, Horowitz MM, Rizzo JD. Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful. *Cancer*. 2017 Dec 01;123(23):4687-4700. PMID: PMC5693638
148. Stroncek DF, **Shaw BE**, Logan BR, Kiefer DM, Savani BN, Anderlini P, Bredeson CN, Hematti P, Ganguly S, Diaz MA, Abdel-Azim H, Ahmed I, Maharaj D, Seftel M, Beitinjaneh A, Seo S, Yared JA, Halter J, O'Donnell PV, Hale GA, DeFilipp Z, Lazarus H, Liesveld JL, Zhou Z, Munshi P, Olsson RF, Kasow KA, Szer J, Switzer GE, Chitphakdithai P, Shah N, Confer DL, Pulsipher MA. Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34⁺ Yields Are Less. *Biol Blood Marrow Transplant*. 2018 Jan;24(1):175-184. PMID: PMC5743544
149. **Shaw BE**, Syrjala KL, Onstad LE, Chow EJ, Flowers ME, Jim H, Baker KS, Buckley S, Fairclough DL, Horowitz MM, Lee SJ. PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. *Cancer*. 2018 Feb 15;124(4):841-849. PMID: PMC5800994
150. Myers RM, Hill BT, **Shaw BE**, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM, Savani BN, Flowers MED, D'Souza A, Ehrhardt MJ, Langston A, Yared JA, Hayashi RJ, Daly A, Olsson RF, Inamoto Y, Malone AK, DeFilipp Z, Margossian SP, Warwick AB, Jaglowski S, Beitinjaneh A, Fung H, Kasow KA, Marks DI, Reynolds J, Stockerl-Goldstein K, Wirk B, Wood WA, Hamadani M, Satwani P. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. *Cancer*. 2018 Feb 15;124(4):816-825. PMID: PMC5871233
151. Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, **Shaw BE**. Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2018 Feb;24(2):228-241. PMID: PMC5768142
152. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, **Shaw B**, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. *Haematologica*. 2018 Apr;103(4):717-727. PMID: PMC5865423
153. **Shaw BE**, Logan BR, Spellman SR, Marsh SGE, Robinson J, Pidala J, Hurley C, Barker J, Maiers M, Dehn J, Wang H, Haagenson M, Porter D, Petersdorf EW, Woolfrey A, Horowitz MM, Verneris M, Hsu KC, Fleischhauer K, Lee SJ. Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. *Biol Blood Marrow Transplant*. 2018 May;24(5):1049-1056. PMID: PMC5953795
154. Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick AB, Wirk BM, Yi J, Battiwalla M, Flowers MDE, Savani B, **Shaw BE**. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. *Bone Marrow Transplant*. 2018 May;53(5):535-555. PMID: PMC5985976
155. Burns LJ, Abbetti B, Arnold SD, Bender J, Doughtie S, El-Jawahiri A, Gee G, Hahn T, Horowitz MM, Johnson S, Juckett M, Krishnamuriti L, Kullberg S, LeMaistre CF, Loren A, Majhail NS, Murphy EA,

- Rizzo D, Roche-Green A, Saber W, Schatz BA, Schmit-Pokorny K, **Shaw BE**, Syrjala KL, Tierney DK, Ullrich C, Vanness DJ, Wood WA, Denzen EM. Engaging Patients in Setting a Patient-Centered Outcomes Research Agenda in Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2018 Jun;24(6):1111-1118. PMID: PMC5993588
156. Arrieta-Bolaños E, Madrigal-Sánchez JJ, Stein JE, Órlich-Pérez P, Moreira-Espinoza MJ, Paredes-Carias E, Vanegas-Padilla Y, Salazar-Sánchez L, Madrigal JA, Marsh SGE, **Shaw BE**. High-resolution HLA allele and haplotype frequencies in majority and minority populations of Costa Rica and Nicaragua: Differential admixture proportions in neighboring countries. *HLA*. 2018 Jun;91(6):514-529.
157. Bhatt NS, Brazauskas R, Tecca HR, Vogel J, Mattila D, Lee SJ, Horowitz MM, Rizzo JD, **Shaw BE**. Female Sex is Associated With Poor Health-related Quality of Life in Children at 12 Months Post-Hematopoietic Cell Transplantation. *J Pediatr Hematol Oncol*. 2019 Apr;41(3):233-237. PMID: PMC6301126
158. Arrieta-Bolaños E, Crivello P, **Shaw BE**, Ahn KW, Wang HL, Verneris MR, Hsu KC, Pidala J, Lee SJ, Fleischhauer K, Spellman SR. In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance. *Blood Adv*. 2018 Jul 24;2(14):1773-1783. PMID: PMC6058232
159. Andermann TM, Peled JU, Ho C, Reddy P, Riches M, Storb R, Teshima T, van den Brink MRM, Alousi A, Balderman S, Chiusolo P, Clark WB, Holler E, Howard A, Kean LS, Koh AY, McCarthy PL, McCarty JM, Mohty M, Nakamura R, Rezvani K, Segal BH, **Shaw BE**, Shpall EJ, Sung AD, Weber D, Whangbo J, Wingard JR, Wood WA, Perales MA, Jenq RR, Bhatt AS, Blood and Marrow Transplant Clinical Trials Network. The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. *Biol Blood Marrow Transplant*. 2018 Jul;24(7):1322-1340. PMID: PMC6045977
160. La Casta AH, **Shaw BE**, Anthias C, Bruce JG, Pastorek G, Billen A, O'Leary A, Switzer GE. Motives for joining an unrelated HSC donor registry: description, categorization, and association with donor availability. *Bone Marrow Transplant*. 2019 Mar;54(3):425-431.
161. Liang J, Lee SJ, Storer BE, **Shaw BE**, Chow EJ, Flowers ME, Krakow EF, Bar M, Syrjala KL, Salit RB, Kurukulasuriya CE, Jim HSL. Rates and Risk Factors for Post-Traumatic Stress Disorder Symptomatology among Adult Hematopoietic Cell Transplant Recipients and Their Informal Caregivers. *Biol Blood Marrow Transplant*. 2019 Jan;25(1):145-150. PMID: PMC6310630
162. D'Souza A, Millard H, Knight J, Brazauskas R, Lee SJ, Flynn KE, Rizzo JD, **Shaw BE**. Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2018 Aug;53(8):1079-1082. PMID: PMC6098949
163. Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, **Shaw BE**, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. *Biol Blood Marrow Transplant*. 2018 Aug;24(8):1664-1670.
164. Nemecek ER, Hilger RA, Adams A, **Shaw BE**, Kiefer D, Le-Rademacher J, Levine JE, Yanik G, Leung W, Talano JA, Haut P, Delgado D, Kapoor N, Petrovic A, Adams R, Hanna R, Rangarajan H, Dalal J, Chewing J, Verneris MR, Epstein S, Burroughs L, Perez-Albuerne ED, Pulsipher MA, Delaney C. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. *Biol Blood Marrow Transplant*. 2018 Aug;24(8):1651-1656. PMID: PMC6108922
165. Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, **Shaw BE**, D'Souza A. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. *Bone Marrow Transplant*. 2018 Sep;53(9):1210-1213.
166. Lee SJ, Onstad L, Chow EJ, **Shaw BE**, Jim HSL, Syrjala KL, Baker KS, Buckley S, Flowers ME. Patient-reported outcomes and health status associated with chronic graft-versus-host disease. *Haematologica*. 2018 Sep;103(9):1535-1541. PMID: PMC6119141
167. Pahnke S, Egeland T, Halter J, Häggglund H, **Shaw BE**, Woolfrey AE, Szer J, Working Group Medical of the World Marrow Donor Association. Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation. *Bone Marrow Transplant*. 2019 Jun;54(6):858-866.
168. Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LE, Logan BR, Ahn KW, **Shaw BE**, Kletzel M, Olszewski M, Khan S, Meshinchi S, Keating A, Harris A, Teira P, Duerst RE, Margossian SP, Martin PL, Petrovic A, Dvorak CC, Nemecek ER, Boyer MW, Chen AR, Davis JH, Shenoy S, Savasan S, Hudspeth MP, Adams RH, Lewis VA, Kheradpour A, Kasow KA, Gillio AP, Haight AE, Bhatia M,

- Bambach BJ, Haines HL, Quigg TC, Greiner RJ, Talano JM, Delgado DC, Cheerva A, Gowda M, Ahuja S, Ozkaynak M, Mitchell D, Schultz KR, Fry TJ, Loeb DM, Pulsipher MA. Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. *Biol Blood Marrow Transplant.* 2018 Oct;24(10):2040-2046. PMID: PMC6239928
169. Duncan CN, Brazauskas R, Huang J, **Shaw BE**, Majhail NS, Savani BN, Flowers MED, Battiwalla M, Beebe K, Dietz AC, Dvorak CC, Giller R, Jacobsohn DA, Kletzel M, Martin PL, Nemecek ER, Nuechterlein B, Talano JA, Pulsipher MA, Baker KS. Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.* 2018 Oct;53(10):1278-1287. PMID: PMC6158112
170. Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, **Shaw BE**, Flowers ME, Ruutu T, Greinix H, Holler E, Basak G, Duarte RF, Pavletic SZ, EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the "EBMT?NIH (National Institutes of Health)?CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force". EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. *Bone Marrow Transplant.* 2018 Nov;53(11):1401-1415. PMID: PMC6786777
171. Radivoyevitch T, Dean RM, **Shaw BE**, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. *Leuk Res.* 2018 Nov;74:130-136. PMID: PMC6219911
172. Inamoto Y, Petri?ek I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovó A, Schears R, Shah A, Agrawal V, Ahmed A, Ahmed I, Ali A, Aljurf M, Alkhateeb H, Beitinjaneh A, Bhatt N, Buchbinder D, Byrne M, Callander N, Fahnehjelm K, Farhadfar N, Gale RP, Ganguly S, Hashmi S, Hildebrandt GC, Horn E, Jakubowski A, Kamble RT, Law J, Lee C, Nathan S, Penack O, Pingali R, Prasad P, Pulanic D, Rotz S, Shreenivas A, Steinberg A, Tabbara K, Tichelli A, Wirk B, Yared J, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, **Shaw BE**, Valdés-Sanz N. Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2019 May;25(5):e145-e154. PMID: PMC6511311
173. Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale GA, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Lupo Stanghellini MT, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E, Lee C, Nathan S, Penack O, Prasad P, Rotz S, Rovó A, Yared J, Pavletic S, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, **Shaw BE**, Petri?ek I. Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. *Bone Marrow Transplant.* 2019 May;54(5):662-673.
174. Fleischhauer K, Hsu KC, **Shaw BE**. Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection. *Bone Marrow Transplant.* 2018 Dec;53(12):1498-1507. PMID: PMC7286200
175. **Shaw BE**. Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective? *Curr Hematol Malig Rep.* 2019 Feb;14(1):22-30. PMID: PMC6408224
176. Norkin M, **Shaw BE**, Brazauskas R, Tecca HR, Leather HL, Gea-Banacloche J, T Kamble R, DeFilipp Z, Jacobsohn DA, Ringden O, Inamoto Y, A Kasow K, Buchbinder D, Shaw P, Hematti P, Schears R, Badawy SM, Lazarus HM, Bhatt N, Horn B, Chhabra S, M Page K, Hamilton B, Hildebrandt GC, Yared JA, Agrawal V, M Beitinjaneh A, Majhail N, Kindwall-Keller T, Olsson RF, Schoemans H, Gale RP, Ganguly S, A Ahmed I, Schouten HC, L Liesveld J, Khera N, Steinberg A, Shah AJ, Solh M,

- Marks DI, Rybka W, Aljurf M, Dietz AC, Gergis U, George B, Seo S, Flowers MED, Battiwalla M, Savani BN, Riches ML, Wingard JR. Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2019 Feb;25(2):362-368. PMID: PMC6339825
177. Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale GA, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Lupo Stanghellini MT, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E, Lee C, Nathan S, Penack O, Prasad P, Rotz S, Rovó A, Yared J, Pavletic S, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, **Shaw BE**, Petri?ek I. Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2019 Feb;25(2):e46-e54. PMID: PMC6362842
 178. Mayor NP, Hayhurst JD, Turner TR, Szydlo RM, **Shaw BE**, Bultitude WP, Sayno JR, Tavarozzi F, Latham K, Anthias C, Robinson J, Braund H, Danby R, Perry J, Wilson MC, Bloor AJ, McQuaker IG, MacKinnon S, Marks DI, Pagliuca A, Potter MN, Potter VT, Russell NH, Thomson KJ, Madrigal JA, Marsh SGE. Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. *Biol Blood Marrow Transplant*. 2019 Mar;25(3):443-450.
 179. Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, **Shaw BE**, Miller JP, Hosoba S, Waller EK, Devine SM. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. *Blood Adv*. 2019 Mar 26;3(6):875-883. PMID: PMC6436017
 180. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman OF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, **Shaw BE**. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. *Haematologica*. 2019 Apr;104(4):844-854. PMID: PMC6442962
 181. Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, **Shaw BE**, Confer DL. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. *Biol Blood Marrow Transplant*. 2019 Apr;25(4):699-711. PMID: PMC6453753
 182. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, **Shaw B**, Saber W, Fenske T, Hamadani M. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. *Biol Blood Marrow Transplant*. 2019 Apr;25(4):827-833.
 183. Inamoto Y, Petri?ek I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovó A, Schears R, Shah A, Agrawal V, Al-Khinji A, Ahmed I, Ali A, Aljurf M, Alkhateeb H, Beitinjaneh A, Bhatt N, Buchbinder D, Byrne M, Callander N, Fahnehjelm K, Farhadfar N, Gale RP, Ganguly S, Hildebrandt GC, Horn E, Jakubowski A, Kamble RT, Law J, Lee C, Nathan S, Penack O, Pingali R, Prasad P, Pulanic D, Rotz S, Shreenivas A, Steinberg A, Tabbara K, Tichelli A, Wirk B, Yared J, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, **Shaw BE**, Valdés-Sanz N. Correction: Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality

- of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. *Bone Marrow Transplant*. 2019 May;54(5):782-783.
184. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Ball ED, Bolwell BJ, Bunin NJ, Cheerva A, Delgado DC, Dvorak CC, Gillio AP, Hahn TE, Hale GA, Haight AE, Hayes-Lattin BM, Kasow KA, Linenberger M, Magalhaes-Silverman M, Mori S, Prasad VK, Quigg TC, Sahdev I, Schriber JR, Shenoy S, Tse WT, Yanik GA, Navarro WH, Horowitz MM, Confer DL, **Shaw BE**, Switzer GE. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. *Biol Blood Marrow Transplant*. 2019 May;25(5):955-964. PMID: PMC6511296
185. Prokopishyn NL, Logan BR, Kiefer DM, Sees JA, Chitphakdithai P, Ahmed IA, Anderlini PN, Beitinjaneh AM, Bredeson C, Cerny J, Chhabra S, Daly A, Diaz MA, Farhadfar N, Frangoul HA, Ganguly S, Gastineau DA, Gergis U, Hale GA, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Murthy HS, Norkin M, Olsson RF, Papari M, Savani BN, Szer J, Waller EK, Wirk B, Yared JA, Pulsipher MA, Shah NN, Switzer GE, O'Donnell PV, Confer DL, **Shaw BE**. The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. *Biol Blood Marrow Transplant*. 2019 Jul;25(7):1325-1330. PMID: PMC6615955
186. Schoemans HM, Finn L, Foster J, Roche-Green A, Bevans M, Kullberg S, Lee E, Sargeant C, Schatz BA, Scheeler K, **Shaw BE**, Shereck E, Murphy EA, Burns LJ, Schmit-Pokorny K. A Conceptual Framework and Key Research Questions in Educational Needs of Blood and Marrow Transplantation Patients, Caregivers, and Families. *Biol Blood Marrow Transplant*. 2019 Jul;25(7):1416-1423.
187. Aljurf M, Weisdorf D, Alfraih F, Szer J, Müller C, Confer D, Hashmi S, Kröger N, **Shaw BE**, Greinix H, Kharfan-Dabaja MA, Foeken L, Seber A, Ahmed S, El-Jawahri A, Al-Awwami M, Atsuta Y, Pasquini M, Hanbali A, Alzahrani H, Okamoto S, Gluckman E, Mohty M, Kodera Y, Horowitz M, Niederwieser D, El Fakih R. "Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries". *Bone Marrow Transplant*. 2019 Aug;54(8):1179-1188. PMID: PMC6760540
188. Wiener L, Hoag JA, Pelletier W, Shah NN, **Shaw BE**, Pulsipher MA, Bruce J, Bader P, Willasch AM, Dalissier A, Guilcher G, Anthias C, Confer DL, Sees JA, Logan B, Switzer GE. Transplant center practices for psychosocial assessment and management of pediatric hematopoietic stem cell donors. *Bone Marrow Transplant*. 2019 Nov;54(11):1780-1788. PMID: PMC6961459
189. **Shaw BE**, D'Souza A, Lee SJ. Importance of Assessing Patient-Reported Outcomes With Salvage Autologous Transplantation in Relapsed Multiple Myeloma. *J Clin Oncol*. 2019 Jul 01;37(19):1598-1600. PMID: PMC6879316
190. Arrieta-Bolaños E, Madrigal-Sánchez JJ, Stein JE, Moreira-Espinoza MJ, Paredes-Carias E, Vanegas-Padilla Y, Salazar-Sánchez L, Madrigal JA, Marsh SGE, **Shaw BE**. 4-Locus high-resolution HLA allele and haplotype frequencies in admixed population from Nicaragua. *Hum Immunol*. 2019 Jul;80(7):417-418.
191. Arrieta-Bolaños E, Madrigal-Sánchez JJ, Stein JE, Salazar-Sánchez L, Madrigal JA, Marsh SGE, **Shaw BE**. 4-Locus high-resolution HLA allele and haplotype frequencies in Amerindians from Costa Rica. *Hum Immunol*. 2019 Jul;80(7):409-410.
192. Arrieta-Bolaños E, Madrigal-Sánchez JJ, Stein JE, Arrieta-Molina G, Grant S, Salazar-Sánchez L, Madrigal JA, Marsh SGE, **Shaw BE**. 4-Locus high-resolution HLA allele and haplotype frequencies in Costa Ricans from African-Caribbean descent. *Hum Immunol*. 2019 Jul;80(7):411-412.
193. Arrieta-Bolaños E, Madrigal-Sánchez JJ, Stein JE, Arrieta-Molina G, Salazar-Sánchez L, Madrigal JA, Marsh SGE, **Shaw BE**. 4-Locus high-resolution HLA allele and haplotype frequencies in Costa Ricans from Guanacaste. *Hum Immunol*. 2019 Jul;80(7):415-416.
194. Arrieta-Bolaños E, Madrigal-Sánchez JJ, Stein JE, Órlich-Pérez P, Arrieta-Molina G, Salazar-Sánchez L, Madrigal JA, Marsh SGE, **Shaw BE**. 5-Locus high-resolution HLA allele and haplotype frequencies in Costa Ricans from the Central Valley. *Hum Immunol*. 2019 Jul;80(7):413-414.
195. Arrieta-Bolaños E, Madrigal-Sánchez JJ, Stein JE, Arrieta-Molina G, Salazar-Sánchez L, Madrigal JA, Marsh SGE, **Shaw BE**. 4-Locus high-resolution HLA allele and haplotype frequencies in Costa Ricans from Guanacaste. *Hum Immunol*. 2019 Jul;80(7):415-416.
196. Mayor NP, Hayhurst JD, Turner TR, Szydlo RM, **Shaw BE**, Bultitude WP, Sayno JR, Tavarozzi F, Latham K, Anthias C, Robinson J, Braund H, Danby R, Perry J, Wilson MC, Bloor AJ, McQuaker IG, MacKinnon S, Marks DI, Pagliuca A, Potter MN, Potter VT, Russell NH, Thomson KJ, Madrigal JA, Marsh SGE. A reply to Hurley et al. regarding Recipients Receiving Better HLA-Matched

- Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. *Biol Blood Marrow Transplant*. 2019 Aug;25(8):e270-e271.
197. Dehn J, Spellman S, Hurley CK, **Shaw BE**, Barker JN, Burns LJ, Confer DL, Eapen M, Fernandez-Vina M, Hartzman R, Maiers M, Marino SR, Mueller C, Perales MA, Rajalingam R, Pidala J. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. *Blood*. 2019 Sep 19;134(12):924-934. PMID: PMC6753623
 198. Pidala J, Mupfudze TG, Payton T, Barker J, Perales MA, **Shaw BE**, Fernández-Viña M, Burns LJ, Dehn J. Urgent Time to Allogeneic Hematopoietic Cell Transplantation: A National Survey of Transplant Physicians and Unrelated Donor Search Coordinators Facilitated by the Histocompatibility Advisory Group to the National Marrow Donor Program. *Biol Blood Marrow Transplant*. 2019 Dec;25(12):2501-2506. PMID: PMC7307219
 199. Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, **Shaw BE**, D'Souza A. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. *Amyloid*. 2019 Dec;26(4):210-215.
 200. Wong WH, Bhatt S, Trinkaus K, Pusic I, Elliott K, Mahajan N, Wan F, Switzer GE, Confer DL, DiPersio J, Pulsipher MA, Shah NN, Sees J, Bystry A, Blundell JR, **Shaw BE**, Druley TE. Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. *Sci Transl Med*. 2020 Jan 15;12(526). PMID: PMC7521140
 201. Ruark J, Mullane E, Cleary N, Cordeiro A, Bezerra ED, Wu V, Voutsinas J, **Shaw BE**, Flynn KE, Lee SJ, Turtle CJ, Maloney DG, Fann JR, Bar M. Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. *Biol Blood Marrow Transplant*. 2020 Jan;26(1):34-43. PMID: PMC6951812
 202. Lee CJ, Kim S, Tecca HR, Bo-Subait S, Phelan R, Brazauskas R, Buchbinder D, Hamilton BK, Battiwala M, Majhail NS, Lazarus HM, Shaw PJ, Marks DI, Litzow MR, Chhabra S, Inamoto Y, DeFilipp Z, Hildebrandt GC, Olsson RF, Kasow KA, Liesveld JL, Rotz SJ, Badawy SM, Bhatt NS, Yared JA, Page KM, Arellano ML, Kent M, Farhadfar N, Seo S, Hematti P, Freytes CO, Rovó A, Ganguly S, Nathan S, Burns L, **Shaw BE**, Muffly LS. Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. *Blood Adv*. 2020 Mar 24;4(6):983-992. PMID: PMC7094022
 203. Anthias C, **Shaw BE**, Bruce JG, Confer DL, Abress LK, Dew MA, Billen A, O'Leary A, Braund H, Switzer GE. Role of Race/Ethnicity in Donor Decisions about Unrelated Hematopoietic Progenitor Cell Donation: Exploring Reasons for Higher Attrition among Racial/Ethnic Minorities. *Biol Blood Marrow Transplant*. 2020 Mar;26(3):593-599.
 204. Buchbinder D, Brazauskas R, Bo-Subait K, Ballen K, Parsons S, John T, Hahn T, Sharma A, Steinberg A, D'Souza A, Kumar AJ, Yoshimi A, Wirk B, **Shaw B**, Freytes C, LeMaistre C, Bredeson C, Dandoy C, Almaguer D, Marks DI, Szwajcer D, Hale G, Schouten H, Hashem H, Schoemans H, Murthy HS, Lazarus HM, Cerny J, Tay J, Yared JA, Adekola K, Schultz KR, Lehmann L, Burns L, Aljurf M, Diaz MA, Majhail N, Farhadfar N, Kamble R, Olsson R, Schears R, Seo S, Beattie S, Chhabra S, Savani BN, Badawy S, Ganguly S, Ciurea S, Marino S, Gergis U, Kuwatsuka Y, Inamoto Y, Khera N, Hashmi S, Wood W, Saber W. Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. *Biol Blood Marrow Transplant*. 2020 Mar;26(3):553-561. PMID: PMC7367505
 205. Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, **Shaw BE**, Hamadani M, Hari PN. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. *Biol Blood Marrow Transplant*. 2020 May;26(5):893-901.
 206. Kahn JM, Brazauskas R, Tecca HR, Bo-Subait S, Buchbinder D, Battiwala M, Flowers MED, Savani BN, Phelan R, Broglie L, Abraham AA, Keating AK, Daly A, Wirk B, George B, Alter BP, Ustun C, Freytes CO, Beitinjaneh AM, Duncan C, Copelan E, Hildebrandt GC, Murthy HS, Lazarus HM, Auletta JJ, Myers KC, Williams KM, Page KM, Vrooman LM, Norkin M, Byrne M, Diaz MA, Kamani N, Bhatt NS, Rezvani A, Farhadfar N, Mehta PA, Hematti P, Shaw PJ, Kamble RT, Schears R, Olsson RF, Hayashi RJ, Gale RP, Mayo SJ, Chhabra S, Rotz SJ, Badawy SM, Ganguly S, Pavletic S, Nishihori T, Prestidge T, Agrawal V, Hogan WJ, Inamoto Y, **Shaw BE**, Satwani P. Subsequent

- neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. *Blood Adv.* 2020 May 12;4(9):2084-2094. PMID: PMC7218429
207. Cusatis RN, Tecca HR, D'Souza A, **Shaw BE**, Flynn KE. Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes. *Cancer.* 2020 Jun 01;126(11):2679-2686. PMID: PMC7220834
208. Farhadfar N, Murthy HS, Logan BR, Sees JA, Ayas M, Battiwalla M, Beitinjaneh AM, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Gergis U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O' Donnell PV, Olsson RF, Rossmann S, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, **Shaw BE**, Wingard JR. Correction: Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. *Bone Marrow Transplant.* 2021 Feb;56(2):522. PMID: PMC7722110
209. Seftel MD, Kuxhausen M, Burns L, Chitphakdithai P, Confer D, Kiefer D, Lee S, Logan B, O'Donnell P, Pulsipher M, Shah NN, Switzer G, **Shaw BE**. Clonal Hematopoiesis in Related Allogeneic Transplant Donors: Implications for Screening and Management. *Biol Blood Marrow Transplant.* 2020 Jun;26(6):e142-e144. PMID: PMC7440392
210. Nacheva E, Ahjee T, Addada J, Navarette C, Pamphilon D, Regan F, Pawson R, Szydlo R, Goldman J, Mackinnon S, **Shaw BE**, Madrigal A. Absence of damaging effects of stem cell donation in unrelated donors assessed by FISH and gene variance screening. *Bone Marrow Transplant.* 2020 Jul;55(7):1290-1296.
211. Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, Saber W, **Shaw BE**, Weisdorf D, Devine SM, Horowitz MM. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. *Biol Blood Marrow Transplant.* 2020 Jul;26(7):1312-1317. PMID: PMC7194895
212. Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, Hebert KM, Arora M, Chhabra S, Devine SM, Hamadani M, D'Souza A, Pasquini MC, Phelan R, Rizzo JD, Saber W, **Shaw BE**, Weisdorf DJ, Horowitz MM. Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. *Biol Blood Marrow Transplant.* 2020 Jul;26(7):e161-e166. PMID: PMC7206419
213. Salit RB, Lee SJ, Burns LJ, **Shaw BE**, Majhail NS, Bhatt NS, Wood WA, Syrjala KL. Return-to-Work Guidelines and Programs for Post-Hematopoietic Cell Transplantation Survivors: An Initial Survey. *Biol Blood Marrow Transplant.* 2020 Aug;26(8):1520-1526. PMID: PMC7546432
214. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, **Shaw BE**, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. *Biol Blood Marrow Transplant.* 2020 Aug;26(8):e177-e182. PMID: PMC7404814
215. Herr MM, Curtis RE, Tucker MA, Tecca HR, Engels EA, Cahoon EK, Battiwalla M, Buchbinder D, Flowers ME, Brazauskas R, **Shaw BE**, Morton LM. Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. *J Am Acad Dermatol.* 2020 Sep;83(3):762-772. PMID: PMC7206613
216. Chhabra S, Abedin S, Graham MB, Ferrer Marrero TM, Hari PN, **Shaw BE**. Letter to the Editor Regarding "Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation". *Biol Blood Marrow Transplant.* 2020 Sep;26(9):e241-e242. PMID: PMC7309826
217. Farhadfar N, Burns LJ, Mupfudze T, **Shaw BE**, Bollard CM, Devine SM, Horowitz MM, Jones RJ, Murthy HS, Wingard JR, Lee SJ. Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023. *Transplant Cell Ther.* 2021 Feb;27(2):183.e1-183.e7. PMID: PMC7546661
218. Dehn J, Chitphakdithai P, **Shaw BE**, McDonald AA, Devine SM, Burns LJ, Spellman S. Likelihood of Proceeding to Allogeneic Hematopoietic Cell Transplantation in the United States after Search Activation in the National Registry: Impact of Patient Age, Disease, and Search Prognosis. *Transplant Cell Ther.* 2021 Feb;27(2):184.e1-184.e13. PMID: PMC8015680
219. Hong S, Brazauskas R, Hebert KM, Ganguly S, Abdel-Azim H, Diaz MA, Beattie S, Ciurea SO, Szwajcer D, Badawy SM, Gratwohl AA, LeMaistre C, Aljurf MDSM, Olsson RF, Bhatt NS, Farhadfar N, Yared JA, Yoshimi A, Seo S, Gergis U, Beitinjaneh AM, Sharma A, Lazarus H, Law J, Ulrickson M, Hashem H, Schoemans H, Cerny J, Rizzieri D, Savani BN, Kamble RT, **Shaw BE**, Khera N, Wood WA, Hashmi S, Hahn T, Lee SJ, Rizzo JD, Majhail NS, Saber W. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. *Cancer.* 2021 Feb 15;127(4):609-618. PMID: PMC7855526

220. Bultitude WP, Schellekens J, Szydlo RM, Anthias C, Cooley SA, Miller JS, Weisdorf DJ, **Shaw BE**, Roberts CH, Garcia-Sepulveda CA, Lee J, Pearce RM, Wilson MC, Potter MN, Byrne JL, Russell NH, MacKinnon S, Bloor AJ, Patel A, McQuaker IG, Malladi R, Tholouli E, Orchard K, Potter VT, Madrigal JA, Mayor NP, Marsh SGE. Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML. *Bone Marrow Transplant.* 2020 Oct;55(10):1975-1984. PMID: PMC8852820
221. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, **Shaw BE**, Horowitz MM, Hari PN, Hamadani M. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant.* 2020 Oct;26(10):1876-1885. PMID: PMC7571859
222. Berro M, Chhabra S, Piñana JL, Arbelbide J, Rivas MM, Basquiera AL, Vitriu A, Requejo A, Milovic V, Yantorno S, Bentolila G, Garcia JJ, Castro M, Palmer S, Saslavsky M, Duarte P, Cerutti A, Jarchum G, Tisi Baña M, Thapa B, Solano C, Sureda A, Rovira M, **Shaw BE**, Kusminsky G, Grupo Argentino de Trasplante de Médula Ósea y Terapia Celular (GATMO-TC). Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score. *Biol Blood Marrow Transplant.* 2020 Oct;26(10):1828-1832.
223. Farhadfar N, Murthy HS, Logan BR, Sees JA, Ayas M, Battiwalla M, Beitinjaneh AM, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Gergis U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O' Donnell PV, Olsson RF, Rossmann S, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, **Shaw BE**, Wingard JR. Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. *Bone Marrow Transplant.* 2020 Nov;55(11):2121-2131. PMID: PMC7606543
224. Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, Wood WA, Brazauskas R, Lehmann L, Pasquini MC, Seber A, Lu PH, Atsuta Y, Riches M, Perales MA, Worel N, Okamoto S, Srivastava A, Chemaly RF, Cordonnier C, Dandoy CE, Wingard JR, Kharfan-Dabaja MA, Hamadani M, Majhail NS, Waghmare AA, Chao N, Kröger N, **Shaw B**, Mohty M, Niederwieser D, Greinix H, Hashmi SK, WBMT and the CIBMTR Health Services and International Studies Committee. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. *Biol Blood Marrow Transplant.* 2020 Dec;26(12):2181-2189. PMID: PMC7380217
225. Switzer GE, Bruce JG, Kiefer DM, Kobusingye H, Abebe KZ, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, **Shaw BE**, Riches M, Hayes-Lattin B, Linenberger M, Bolwell B, Rowley SD, Litzow MR, Pulsipher MA. Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study. *Biol Blood Marrow Transplant.* 2020 Dec;26(12):2365-2371. PMID: PMC7686016
226. Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales MA, Seropian S, **Shaw BE**, Tuschl EE, Zeidan AM, Riches ML, Shah GL. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. *Lancet Haematol.* 2021 Mar;8(3):e185-e193. PMID: PMC7816949
227. Worel N, **Shaw BE**, Aljurf M, Koh M, Seber A, Weisdorf D, Schwartz J, Galeano S, Kodera Y, Eldridge PW, Hashmi S, Atsuta Y, Szer J, Saber W, Niederwieser D, Greinix HT. Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation Transplantation and Cellular Therapy. 2021.
228. El Fakih R, Greinix H, Koh M, **Shaw B**, Mohty M, Al Nahedh M, Saber W, Kharfan-Dabaja MA, Perales MA, Savani BN, Majhail NS, Passweg JR, Sureda A, Ahmed SO, Gluckman E, Riches M, El-Jawahri A, Rondelli D, Srivastava A, Faulkner L, Atsuta Y, Ballen KK, Rasheed W, Okamoto S, Seber A, Chao N, Kröger N, Kodera Y, Szer J, Hashmi SK, Horowitz MM, Weisdorf D, Niederwieser D, Aljurf M. Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program Transplantation and Cellular Therapy. 2021.
229. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, **Shaw BE**, Horowitz MM, Hari PN, Hamadani M. Corrigendum to 'Ixazomib for chronic Graft-Versus-Host

- Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885] (Biology of Blood and Marrow Transplantation (2020) 26/10(1876-1885) (S1083879120304146), (10.1016/j.bbmt.2020.07.005)) Transplantation and Cellular Therapy. 2021.
230. Seftel MD, Chitphakdithai P, Miller JP, Kobusingye H, Logan BR, Linenberger M, Artz AS, Haight AE, Jacobsohn DA, Litzow MR, Magalhaes-Silverman M, Selby GB, Vusirikala M, Horowitz MM, Switzer GE, Confer DL, **Shaw BE**, Pulsipher MA. Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study Transplantation and Cellular Therapy. 2021.
231. Panch SR, Logan B, Sees JA, Bo-Subait S, Savani B, Shah NN, Hsu JW, Switzer G, Lazarus HM, Anderlini P, Hematti P, Confer D, Pulsipher MA, **Shaw BE**, Stroncek DF. Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. *Transplant Cell Ther.* 2021 Jun;27(6):503.e1-503.e8. PMID: PMC8217152
232. Worel N, **Shaw BE**, Aljurf M, Koh M, Seber A, Weisdorf D, Schwartz J, Galeano S, Kodera Y, Eldridge PW, Hashmi S, Atsuta Y, Szer J, Saber W, Niederwieser D, Greinix HT, Worldwide Network for Blood & Marrow Transplantation. Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation. *Transplant Cell Ther.* 2021 Mar;27(3):270.e1-270.e6. PMID: PMC7834678
233. Hsu JW, Farhadfar N, Murthy H, Logan BR, Bo-Subait S, Frey N, Goldstein SC, Horowitz MM, Lazarus H, Schwanke JD, Shah NN, Spellman SR, Switzer GE, Devine SM, **Shaw BE**, Wingard JR. The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. *Transplant Cell Ther.* 2021 Jun;27(6):507-516. PMID: PMC8217124
234. Mayor NP, Wang T, Lee SJ, Kuxhausen M, Vierra-Green C, Barker DJ, Auletta J, Bhatt VR, Gadalla SM, Gragert L, Inamoto Y, Morris GP, Paczesny S, Reshef R, Ringdén O, **Shaw BE**, Shaw P, Spellman SR, Marsh SGE. Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. *J Clin Oncol.* 2021 Jul 20;39(21):2397-2409. PMID: PMC8280068
235. Seftel MD, Chitphakdithai P, Miller JP, Kobusingye H, Logan BR, Linenberger M, Artz AS, Haight AE, Jacobsohn DA, Litzow MR, Magalhaes-Silverman M, Selby GB, Vusirikala M, Horowitz MM, Switzer GE, Confer DL, **Shaw BE**, Pulsipher MA. Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study. *Transplant Cell Ther.* 2021 Apr;27(4):352.e1-352.e5. PMID: PMC8036235
236. Logan BR, Maiers MJ, Sparapani RA, Laud PW, Spellman SR, McCulloch RE, **Shaw BE**. Optimal Donor Selection for Hematopoietic Cell Transplantation Using Bayesian Machine Learning. *JCO Clin Cancer Inform.* 2021 May;5:494-507. PMID: PMC8443829
237. **Shaw BE**, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. *J Clin Oncol.* 2021 Jun 20;39(18):1971-1982. PMID: PMC8260905
238. Kelly DL, Syrjala K, Taylor M, Rentscher KE, Hashmi S, Wood WA, Jim H, Barata A, Flynn KE, Burns LJ, **Shaw BE**, Petersdorf E, Yero AC, Emmrich AD, Morris KE, Costanzo ES, Knight JM. Biobehavioral Research and Hematopoietic Stem Cell Transplantation: Expert Review from the Biobehavioral Research Special Interest Group of the American Society for Transplantation and Cellular Therapy. *Transplant Cell Ther.* 2021 Sep;27(9):747-757. PMID: PMC8428782
239. Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, **Shaw BE**, Walters MC, Foley A, Devine SM, Horowitz MM. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. *Transplant Cell Ther.* 2021 Nov;27(11):885-907. PMID: PMC8556300
240. Hough R, Lopes A, Patrick P, Russell N, Raj K, Tholouli E, A Snowden J, Collin M, El-Mehidi N, Lawrie A, Clifton-Hadley L, Veys P, Craddock C, Mackinnon S, Cook G, **Shaw B**, Marks D. Primary graft failure, but not relapse, may be identified by early chimerism following double cord blood unit transplantation. *Blood Adv.* 2022 Apr 12;6(7):2414-2426. PMID: PMC9006284

241. Cusatis R, Flynn KE, Vasu S, Pidala J, Muffly L, Uberti J, Tamari R, Mattila D, Mussetter A, Bruzauskas R, Chen M, Leckrone E, Myers J, Mau LW, Rizzo JD, Saber W, Horowitz M, Lee SJ, Burns LJ, **Shaw B**. Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry. *Transplant Cell Ther.* 2022 Feb;28(2):112.e1-112.e9. PMID: PMC8915447
242. Fuchs EJ, McCurdy SR, Solomon SR, Wang T, Herr MR, Modi D, Grunwald MR, Nishihori T, Kuxhausen M, Fingerson S, McKallor C, Bashey A, Kasamon YL, Bolon YT, Saad A, McGuirk J, Paczesny S, Gadalla SM, Marsh SGE, **Shaw BE**, Spellman SR, Lee SJ, Petersdorf EW. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. *Blood.* 2022 Mar 10;139(10):1452-1468. PMID: PMC8914182
243. Bhatt NS, Brazauskas R, Salit RB, Syrjala K, Bo-Subait S, Tecca H, Badawy SM, Baker KS, Beitinjaneh A, Bejanyan N, Byrne M, Dias A, Farhadfar N, Freytes CO, Ganguly S, Hashmi S, Hayashi RJ, Hong S, Inamoto Y, Jamani K, Kasow KA, Khera N, Krem MM, Lazarus HM, Lee CJ, Lee S, Majhail NS, Malone AK, Marks DI, Mau LW, Mayo SJ, Muffly LS, Nathan S, Nishihori T, Page KM, Preussler J, Rangarajan HG, Rotz SJ, Salooja N, Savani BN, Schears R, Schechter-Finkelstein T, Schiller G, Shah AJ, Sharma A, Wang T, Wirk B, Battiwalla M, Schoemans H, Hamilton B, Buchbinder D, Phelan R, **Shaw B**. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. *Transplant Cell Ther.* 2021 Aug;27(8):679.e1-679.e8. doi: 10.1016/j.jct.2021.04.013. Epub 2021 Apr 22. PubMed PMID: 33895402; PubMed Central PMCID: PMC8425287
244. Jöris MM, Schmidt AH, Bernas SN, Feinberg J, Sacchi N, Elmoazzen H, Fournier D, Oguz F, Oliveira D, Yang KL, Mousavi SA, Moomivand S, Abecasis M, Villa J, Fechter MM, Seval GC, Jeyarajah T, Devine SM, **Shaw BE**, Galarza P, Malan R, Harvey C, Forman SJ, Foeken L. Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020-Report from World Marrow Donor Association. *Bone Marrow Transplant.* 2022 Jun;57(6):1021-1024. PMID: PMC8994088
245. Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, Burns LJ, Chhabra S, Christianson D, Cusatis R, Devine SM, D'Souza A, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini M, Pérez WS, Riches M, Rizzo D, Saber W, Spellman SR, Stefanski HE, Steinert P, Weisdorf D, Horowitz M, Auletta JJ, **Shaw BE**, Arora M. Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. *Transplant Cell Ther.* 2022 Jul;28(7):409.e1-409.e10. PMID: PMC9840526
246. Bhatt NS, Brazauskas R, Salit RB, Syrjala K, Bo-Subait S, Tecca H, Badawy SM, Baker KS, Beitinjaneh A, Bejanyan N, Byrne M, Dias A, Farhadfar N, Freytes CO, Ganguly S, Hashmi S, Hayashi RJ, Hong S, Inamoto Y, Jamani K, Kasow KA, Khera N, Krem MM, Lazarus HM, Lee CJ, Lee S, Majhail NS, Malone AK, Marks DI, Mau LW, Mayo SJ, Muffly LS, Nathan S, Nishihori T, Page KM, Preussler J, Rangarajan HG, Rotz SJ, Salooja N, Savani BN, Schears R, Schechter-Finkelstein T, Schiller G, Shah AJ, Sharma A, Wang T, Wirk B, Battiwalla M, Schoemans H, Hamilton B, Buchbinder D, Phelan R, **Shaw B**. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. *Transplant Cell Ther.* 2021 Aug;27(8):679.e1-679.e8. PMID: PMC8425287
247. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, **Shaw BE**, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [*Transplantation and Cellular Therapy* 26/8 (2020) e177-e182] (*Transplantation and Cellular Therapy* (2020) 26/8(e177-e182) (S1083879120302251), (10.1016/j.bbmt.2020.04.013)) *Transplantation and Cellular Therapy.* 2021.
248. Farhadfar N, Ahn KW, Bo-Subait S, Logan B, Stefanski HE, Hsu JW, Panch S, Confer D, Liu H, Badawy SM, Beitinjaneh A, Diaz MA, Hildebrandt GC, Kelkar AH, Lazarus HM, Murthy HS, Preussler JM, Schears RM, Sharma A, van der Poel M, Bruce JG, Pulsipher MA, **Shaw BE**, Wingard JR, Switzer GE. The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials. *Transplant Cell Ther.* 2022 Sep;28(9):603.e1-603.e7. PMID: PMC9427696
249. **Shaw BE**. Patient and donor selection and workup for hematopoietic cell transplantation Hematopoietic Cell Transplantation for Malignant Conditions. 1 January 2019:85-97.
250. Worel N, Aljurf M, Anthias C, Buser AS, Cody M, Fechter M, Galeano S, Greinix HT, Kisch AM, Koh

- MBC, Mengling T, Nicoloso G, Niederwieser D, Pulsipher MA, Seber A, **Shaw BE**, Stefanski HE, Switzer GE, Szer J, van Walraven SM, Yang H, Halter JP. Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues *The Lancet Haematology*. August 2022;9(8):e605-e614.
251. Krishnamurti L, Arnold SD, Haight A, Abraham A, Guilcher GM, John T, Bakshi N, Shenoy S, Syrjala K, Martin PL, Chaudhury S, Eames G, Olowoselu OF, Hsieh M, De La Fuente J, Kasow KA, Stenger E, Mertens A, El-Rassi F, Lane P, **Shaw BE**, Meacham L, Archer D. Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility Study. *JMIR Res Protoc*. 2022 Jul 06;11(7):e36780. PMID: PMC9301564
252. Worel N, Aljurf M, Anthias C, Buser AS, Cody M, Fechter M, Galeano S, Greinix HT, Kisch AM, Koh MBC, Mengling T, Nicoloso G, Niederwieser D, Pulsipher MA, Seber A, **Shaw BE**, Stefanski HE, Switzer GE, Szer J, van Walraven SM, Yang H, Halter JP. Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues. *Lancet Haematol*. 2022 Aug;9(8):e605-e614.
253. Meyer E, Pavlova A, Gandhi A, Hoeg R, Oliai C, Mehta R, Srour S, McGuirk J, Waller E, Fernhoff N, Killian MS, McClellan J, Putnam A, **Shaw B**, Abedi M, Negrin R. CT-524 Orca-T, A Precision Engineered Allograft, Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies Clinical Lymphoma, Myeloma and Leukemia. October 2022;22:S447.
254. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, **Shaw BE**, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [Transplantation and Cellular Therapy 26/8 (2020) e177-e182]. *Transplant Cell Ther*. 2022 Oct;28(10):715-716.
255. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, **Shaw BE**, Horowitz MM, Hari PN, Hamadani M. Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]. *Transplant Cell Ther*. 2022 Oct;28(10):717.
256. Cusatis R, Balza J, Uttke Z, Kode V, Suelzer E, **Shaw BE**, Flynn KE. Patient-reported cognitive function among hematopoietic stem cell transplant and cellular therapy patients: a scoping review. *Qual Life Res*. 2023 Apr;32(4):939-964. PMID: PMC10259487
257. Cusatis R, Martens MJ, Nakamura R, Cutler CS, Saber W, Lee SJ, Logan BR, **Shaw BE**, Gregory A, D'Souza A, Hamilton BK, Horowitz MM, Flynn KE. Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102. *Am J Hematol*. 2023 Feb;98(2):229-250. PMID: PMC9839494
258. Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, Moissev I, Sanchez-Ortega I, Srivastava A, Atsuta Y, Carpenter P, Koreth J, Kroger N, Ljungman P, Page K, Papat U, **Shaw BE**, Sureda A, Soiffer R, Vasu S. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. *Transplant Cell Ther*. 2023 Mar;29(3):151-163. PMID: PMC10119629
259. Hong S, Zhao J, Wang S, Wang H, Lee JH, Farhadfar N, McGuirk JP, Savani BN, Shahrukh HK, Stiff P, Khera N, Hahn T, Loren AW, Jaglowski SM, Wood WA, Saber W, Cerny J, Holtan SG, Reynolds JM, Deol A, Jim H, Uberti J, Whalen V, Yi JC, Preussler J, Baker KS, **Shaw BE**, Devine S, Syrjala K, Majhail NS, Wingard JR, Al-Mansour Z. Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors. *Transplant Cell Ther*. 2023 Mar;29(3):202.e1-202.e8. PMID: PMC10165614
260. Guru Murthy GS, Logan BR, Bo-Subait S, Beitinjaneh A, Devine S, Farhadfar N, Gowda L, Hashmi S, Lazarus H, Nathan S, Sharma A, Yared JA, Stefanski HE, Pulsipher MA, Hsu JW, Switzer GE, Panch SR, **Shaw BE**. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. *Am J Hematol*. 2023 Apr;98(4):608-619. PMID: PMC10290878
261. **Shaw BE**, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A,

- Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial. *Transplant Cell Ther.* 2023 Mar;29(3):208.e1-208.e6. PMID: PMC9992261
262. Bhatt NS, Brazauskas R, Torres AP, Phelan R, **Shaw BE**. Relationship between work performance and quality of life in long-term survivors of pediatric and adolescent hematopoietic cell transplant. *J Cancer Surviv.* 2022 Dec 30:1-9. PMID: PMC9803401
263. Akinola IM, Cusatis R, Pasquini MC, **Shaw BE**, Bollu V, Dalal A, Tesfaye M, Flynn KE. Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T. *Transplant Cell Ther.* 2023 Apr;29(4):254.e1-254.e9. PMID: PMC10369368
264. Gragert L, Spellman SR, **Shaw BE**, Maiers M. Unrelated Stem Cell Donor HLA Match Likelihood in the US Registry Incorporating HLA-DPB1 Permissive Mismatching. *Transplant Cell Ther.* 2023 Apr;29(4):244-252. PMID: PMC10040431
265. Auletta JJ, Kou J, Chen M, Bolon YT, Broglie L, Bupp C, Christianson D, Cusatis RN, Devine SM, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Perez WS, Phelan R, Riches ML, Rizzo JD, Saber W, Spellman SR, Stefanski HE, Steinert P, Tuschl E, Yusuf R, Zhang MJ, **Shaw BE**. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. *Transplant Cell Ther.* 2023 Jun;29(6):346.e1-346.e10. PMID: PMC10239334
266. Devine SM, Bo-Subait S, Kuxhausen M, Spellman SR, Bupp C, Ahn KW, Stefanski HE, Auletta JJ, Logan BR, **Shaw BE**. Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic. *Blood Adv.* 2023 Oct 10;7(19):5982-5993. PMID: PMC10580174
267. Phelan R, Passweg JR, Baldomero H, Iida M, Atsuta Y, Okamoto S, Aljurf M, Alfraih F, **Shaw BE**. International Blood and Marrow Registries: trends on long-term data collection Blood and Marrow Transplantation Long Term Management: Survivorship after Transplant: Second Edition. 1 January 2021:6-13.
268. Cusatis R, Ibrahim A, Knight JM, D'Souza A, **Shaw BE**. Prevalence of Sleep Aid Medication Use in Patients Receiving a Hematopoietic Cell Transplant on an Inpatient Unit. *Hematol Oncol Stem Cell Ther.* 2023 May 23;16(4):366-369.
269. Taylor MR, Cole SW, Strom J, Brazauskas R, Baker KS, Phelan R, Buchbinder D, Hamilton B, Schoemans H, **Shaw BE**, Sharma A, Bhatt NS, Badawy SM, Winestone LE, Preussler JM, Mayo S, Jamani K, Nishihori T, Lee MA, Knight JM. Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis. *Blood Adv.* 2023 Nov 28;7(22):6830-6838. PMID: PMC10679811

Books, Chapters, and Reviews

1. Bower M, Bowles KM, Dark GG, Galvani DW, **Shaw BE**. Haematology and Oncology. In: Medical Masterclass. Firth J, ed. London: Blackwell Science; 2001.
2. **Shaw BE**, O'Connor S, Haynes AP. Lymphoproliferative Disorders Including Chronic Lymphocytic Leukaemia. In: ABC of Clinical Haematology 3rd edition. Provan, D, ed. London: Blackwell BMJ Books; 2007.
3. Bower M, Bowles KM, Brock CS, Dark GG, Fife KM, Galvani DW, Olujohungbe ABK, **Shaw BE**. Haematology and Oncology. In: Medical Masterclass. Second edition. Firth J, ed. London: Royal College of Physicians of London; 2008.
4. **Shaw BE**. HLA matching, compatibility testing and donor selection. In: Haematopoietic Stem Cell Transplantation in Clinical Practice. John Barrett & Jennie Treleaven, ed. London: Churchill Livingstone Elsevier; 2009.
5. **Shaw BE**, Madrigal A. Immunogenetics of allogeneic HSCT. In: ESH-EBMT Handbook on HSCT (6th Edition). Eds: Apperley J, Carreras E, Gluckman E, Masszi T; 2012.
6. **Shaw BE** and Spellman SR. HLA typing and implications. In: Clinical Manual of Blood and Bone Marrow Transplantation. Eds: Abutalib SA, Hari P. Wiley-Blackwell, June 2017.
7. Spellman SR, **Shaw BE**. Unrelated Donor Selection: Human Leukocyte Antigen Testing and Matching – Permissive and Non-permissive Matches. In: Hematopoietic Cell Transplants Hardback with Online Resource: Concepts, Controversies and Future Directions (1st Edition). Editors: Hillard M. Lazarus, Robert Peter Gale, Armand Keating, Andrea Bacigalupo, Reinhold Munker, Kerry Atkinson, Syed Ali

- Abutalib. Cambridge University Press, 2017.
8. Bowles KM, Collins A, **Shaw BE**, Thomas W. Haematology and Oncology. In: Medical Masterclass (3rd edition). Bowles KM, Ed. Firth J, ed-in-chief. London: Royal College of Physicians of London; 2018.
 9. **Shaw BE**. Patient and Donor Selection and Workup for Hematopoietic Cell Transplantation. In: Hematopoietic Cell Transplantation for Malignant Conditions. Editors: Qaiser Bashir and Mehdi Hamadani. Elsevier, 2019.

Abstracts

1. **Shaw BE**, Brazauskas R, Millard HR, Fonstad R, Flynn K, Abernethy A, Vogel J, Petroske C, Mattila D, Drexler R, Lee SJ, Horowitz MM, Rizzo JD. Centralized patient reported quality of life collection in HCT patients is feasible, and higher pre-HCT scores significantly predict better overall survival post-transplant: Oral Presentations at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation; Valencia Spain; April 3 - 6, 2016.
2. **Shaw BE**, Brazauskas R, Millard HR, Fonstad R, Flynn KE, Abernethy A, Vogel J, Petroske C, Mattila D, Drexler R, Lee SJ, Horowitz MM, Rizzo JD. Patient-reported outcome scores significantly predict overall survival for patients undergoing allogeneic hematopoietic cell transplants: Oral Presentations at ISOQOL 23rd Annual Conference, Copenhagen, Denmark; October 22, 2016.
3. **Shaw BE**, Onstad L, Baker KS, Chow EJ, Flowers MED, Jim H, Syrjala KL, Lee SJ. PROMIS and SF36 Patient Reported Outcome Scores Are Strongly Correlated in Transplant Survivors. Oral Presentations at Blood and Marrow Transplantation Tandem meeting, Orlando, Florida; February 2017.
4. **Shaw BE**, Jensen RE, Onstad L, Syrjala KL, Chow EJ, Flowers ME, Jim H, Baker KS, Buckley S, Fairclough DL, Horowitz MM, Lee SJ. PROMIS in Hematopoietic cell transplantation (HCT). Oral Presentations at PROMIS Health Organization Conference, Philadelphia, Pennsylvania; October 2017.
5. **Shaw BE**, Logan BR, Spellman SR, Marsh SGE, Robinson J, Pidala J, Hurley C, Barker J, Maiers M, Dehn J, Wang H, Haagenson M, Porter D, Petersdorf EW, Woolfrey A, Horowitz MM, Verneris M, Hsu KC, Fleischhauer K, Lee SJ. Analysis of 10,462 8/8 HLA- matched unrelated donor transplants could not identify a donor selection score, as younger age is the only significant donor characteristic associated with survival. Oral Presentations at ASH, Atlanta, Georgia; December 2017.
6. **Shaw BE**, Burns LJ, Mattila D, Mussetter A, Chen M, Vasu S, Pidala J, Muffly L, Uberti J, Tamari R, Leckrone E, Myers J, Bruzauskas R, Mau LW, Rizzo D, Saber W, Horowitz M, Lee S, Flynn K. Feasibility of centralized electronic Patient-Reported Outcome (ePRO) collection by an outcome registry, a CIBMTR study of patients on the Centers for Medicaid & Medicare Coverage with Evidence Development (CMS CED) myelodysplasia protocol. Oral Presentations at TCT, Orlando, Florida; February 2020.
7. **Shaw BE**, Mattila D, Burns LJ, Brazauskas R, Leckrone E, Cusatis R, Flynn KE. Incorporating PROs in the CIBMTR hematopoietic cell transplant outcomes registry to enhance QOL research. Oral Presentations at PHO, virtual platform; October 2020.
8. **Shaw BE**, Burns LJ, Mattila D, Mussetter A, Chen M, Vasu S, Pidala J, Muffly L, Uberti J, Tamari R, Leckrone E, Myers J, Bruzauskas R, Mau LW, Rizzo JD, Saber W, Horowitz M, Lee S, Flynn K. Allogeneic hematopoietic cell transplantation (HCT) for patients over 65 years old is not associated with worse symptoms/function than younger patients, a Center for International Blood and Marrow Transplant Research (CIBMTR) study of patients on the Centers for Medicaid & Medicare Coverage with Evidence Development (CMS CED) myelodysplasia protocol. Oral Presentations at ISOQOL, virtual platform; October 2020.